

# CITATION REPORT

List of articles citing

**Causality assessment of adverse reactions to drugs--I.  
A novel method based on the conclusions of  
international consensus meetings: application to  
drug-induced liver injuries**

**DOI: 10.1016/0895-4356(93)90101-6**

**Journal of Clinical Epidemiology, 1993, 46, 1323-30.**

**Source:** <https://exaly.com/paper-pdf/24214193/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1205	Hepatic Adverse Drug Reactions. 459-474		
1204	Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. <i>Journal of Clinical Epidemiology</i> , <b>1993</b> , 46, 1331-6	5.7	400
1203	Reliability of a modified medication appropriateness index in ambulatory older persons. <b>1997</b> , 31, 543-8		84
1202	From Causality Assessment to Product Labeling. <b>1997</b> , 31, 849-856		1
1201	Acute liver injury related to the use of niperotidine. <b>1997</b> , 27, 583-6		17
1200	Suspected carbamazepine-induced hepatotoxicity. <b>1999</b> , 19, 252-5		15
1199	Detection and incidence of drug-induced liver injuries in hospital: a prospective analysis from laboratory signals. <b>2000</b> , 50, 479-84		49
1198	Liver injury caused by ebrotidine: a new example of the utility of the postmarketing surveillance. <b>2000</b> , 56, 187-9		6
1197	Determining Causation from Case Reports. 525-538		5
1196	Methodology for assessing drug-drug interaction evidence in the peer-reviewed medical literature. <b>2000</b> , 61, 553-568		7
1195	Assessing causality in drug-induced liver injury. <b>2000</b> , 33, 1003-5		42
1194	Drug-induced liver disorders: implications for drug development and regulation. <b>2001</b> , 24, 483-90		179
1193	Liver biopsy in elevated liver functions tests? An old question revisited. <b>2001</b> , 35, 290-4		40
1192	Acute fatal hepatitis related to sertraline. <b>2001</b> , 35, 683-4		23
1191	The low incidence of primary liver disease in patients with nonalcoholic steatohepatitis. <b>2001</b> , 35, 684-5		2
1190	[Utility of registries of hepatotoxicity caused by drugs]. <b>2001</b> , 24, 250-5		2
1189	Hepatotoxicity in patients with cirrhosis, an often unrecognized problem: lessons from a fatal case related to amoxicillin/clavulanic acid. <b>2001</b> , 46, 1416-9		9

1188	Comparison of two clinical scales for causality assessment in hepatotoxicity. <b>2001</b> , 33, 123-30	181
1187	Causality assessment versus guilt-by-association in drug hepatotoxicity. <b>2001</b> , 33, 308-10	119
1186	Spontaneous adverse event signaling methods: classification and use with health care treatment products. <b>2001</b> , 23, 191-210	19
1185	Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States. <b>2002</b> , 97, 1198-203	59
1184	Caroli's syndrome in two siblings. <b>2002</b> , 97, 1855-6	2
1183	Algorithms. 229-246	7
1182	Herbal medicine and false-positive results on lymphocyte transformation test. <b>2002</b> , 122, 399-402	9
1181	Cholestatic hepatitis related to use of irbesartan: a case report and a literature review of angiotensin II antagonist-associated hepatotoxicity. <b>2002</b> , 14, 887-90	36
1180	Chronic hepatitis C, ibuprofen, and liver damage. <b>2002</b> , 97, 1854-5	14
1179	Caroli's syndrome in two siblings. <b>2002</b> , 97, 1855-1856	1
1178	Acute, serious drug-induced liver injury. <b>2002</b> , 37, 675-7	13
1177	Unilateral pallidal stimulation for segmental cervical and truncal dystonia: which side?. <b>2002</b> , 17, 1383-5	24
1176	[Tetrabamate-induced hepatotoxicity. Report of seven cases and literature review]. <b>2002</b> , 25, 589-93	6
1175	Drug hepatotoxicity. <b>2002</b> , 6, 381-97	70
1174	Overview Spontaneous Signalling. 247-271	6
1173	Incidence and clinical features of liver injury related to Kampo (Japanese herbal) medicine in 2,496 cases between 1979 and 1999: problems of the lymphocyte transformation test as a diagnostic method. <b>2002</b> , 9, 280-7	42
1172	Oculo-auricular phenomenon secondary to vestibular dysfunction. <b>2002</b> , 17, 1394-5	1
1171	Hemichorea as an initial manifestation of moyamoya disease: reversible striatal hypoperfusion demonstrated on single photon emission computed tomography. <b>2002</b> , 17, 1380-3	42

1170	Cabergoline plasma concentration is increased during concomitant treatment with itraconazole. <b>2002</b> , 17, 1360-2	8
1169	Steele-Richardson-Olszewski syndrome in a patient with a single C212Y mutation in the parkin protein. <b>2002</b> , 17, 1374-80	50
1168	Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson's disease. <b>2002</b> , 17, 1371-4	228
1167	Hereditary chin trembling: a new family with exclusion of the chromosome 9q13-q21 Locus. <b>2002</b> , 17, 1390-2	19
1166	Holmes' tremor and neuroparacoccidioidomycosis: a case report. <b>2002</b> , 17, 1392-4	17
1165	Clozapine withdrawal symptoms in a Parkinson's disease patient. <b>2002</b> , 17, 1365-7	16
1164	Forty-one year follow-up of childhood-onset opsoclonus-myoclonus-ataxia: cerebellar atrophy, multiphasic relapses, and response to IVIG. <b>2002</b> , 17, 1387-90	24
1163	Hemiballism after subthalamotomy in patients with Parkinson's disease: report of 2 cases. <b>2002</b> , 17, 1367-71	41
1162	Further case of paroxysmal exercise-induced dystonia and some insights into pathogenesis. <b>2002</b> , 17, 1386-7	12
1161	Entacapone-induced hepatotoxicity and hepatic dysfunction. <b>2002</b> , 17, 1362-5; discussion 1397-1400	32
1160	Allergic cholestatic hepatitis and exanthema induced by metamizole: verification by lymphocyte transformation test. <b>2002</b> , 22, 507-13	20
1159	Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. <b>2002</b> , 35, 883-9	319
1158	Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. <b>2003</b> , 37, 924-30	306
1157	Diagnosis of drug-induced liver injury in Japanese patients by criteria of Consensus Meetings in Europe. <b>2003</b> , 25, 1-7	6
1156	Assessment of 287 Japanese cases of drug induced liver injury by the diagnostic scale of the International Consensus Meeting. <b>2003</b> , 27, 192-195	62
1155	Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindole. <b>2003</b> , 12, 271-81	83
1154	Leukotriene antagonists. <b>2003</b> , 7, 501-12, viii	8
1153	Hepatitis aguda por bentazepam. <b>2003</b> , 120, 678-679	0

1152	Drug-induced hepatotoxicity. <b>2003</b> , 349, 474-85	1016
1151	Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. <b>2003</b> , 327, 18-22	123
1150	Drug-induced hepatitis due to repeated use of hair dye. <b>2003</b> , 42, 1104-6	6
1149	Hepatic injury in 12 patients taking the herbal weight loss AIDS Chaso or Onshido. <b>2003</b> , 139, 488-92	68
1148	Terbinafine hepatotoxicity. A case report and review of literature. <b>2003</b> , 2, 47-51	23
1147	Thyroid function alterations following quetiapine initiation in a developmentally disabled adolescent. <b>2004</b> , 38, 1541-2	9
1146	Is the Naranjo probability scale accurate enough to ascertain causality in drug-induced hepatotoxicity?. <b>2004</b> , 38, 1540-1	17
1145	Anesthetic and Obstetric Management of High-Risk Pregnancy. <b>2004</b> ,	3
1144	Nonsteroidal anti-inflammatory drug-induced liver injury: a case-control study in primary care. <b>2004</b> , 18, 201-6	42
1143	HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. <b>2004</b> , 39, 1603-12	120
1142	Validity study of a new diagnostic scale for drug-induced liver injury in Japan-comparison with two previous scales. <b>2004</b> , 30, 148-154	38
1141	Clinical perspectives on xenobiotic-induced hepatotoxicity. <b>2004</b> , 36, 301-12	85
1140	Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid. <b>2004</b> , 41, 1062-4	85
1139	Acute hepatitis of cholestatic type possibly associated with the use of glucomannan (amorphophalus konjac). <b>2004</b> , 41, 1061-2	18
1138	Clinical Analysis of Adverse Drug Reactions: A Primer for Clinicians. <b>2004</b> , 39, 697-712	5
1137	Subfulminant liver failure associated with quetiapine. <b>2004</b> , 16, 1415-8	30
1136	Acute hepatitis due to buprenorphine administration. <b>2004</b> , 16, 1033-7	43
1135	Fulminant hepatitis during self-medication with hydroalcoholic extract of green tea. <b>2005</b> , 17, 1135-7	106

1134	Challenges in systematic reviews that assess treatment harms. <b>2005</b> , 142, 1090-9	97
1133	A proposal of the diagnostic scale of drug-induced liver injury. <b>2005</b> , 32, 250-1	47
1132	Patient characteristics in ticlopidine hydrochloride-induced liver injury: Case-control study. <b>2005</b> , 33, 234-40	13
1131	Veterinary pharmacovigilance. Part 5. Causality and expectedness. <b>2005</b> , 28, 203-11	7
1130	Troglitazone and liver injury: in search of answers. <b>2005</b> , 41, 237-46	99
1129	Outcome and prognostic markers in severe drug-induced liver disease. <b>2005</b> , 42, 481-9	441
1128	Acute liver failure due to amoxicillin and amoxicillin/clavulanate. <b>2005</b> , 50, 1785-90	64
1127	Autoimmune hepatitis triggered by acute hepatitis A. <b>2005</b> , 11, 6069-71	30
1126	Proposal of diagnostic criteria of drug induced hepatic injury in DDW-J2004 workshop.. <b>2005</b> , 46, 85-90	64
1125	A case of autoimmune hepatitis superimposed by Ukon-induced liver injury. <b>2005</b> , 46, 26-32	1
1124	Hepatotoxicity of NONI juice: report of two cases. <b>2005</b> , 11, 4758-60	100
1123	Hepatocellular enzyme elevations in a patient receiving ceftriaxone. <b>2005</b> , 62, 2006-10	13
1122	Recognizing drug-induced liver injury: current problems, possible solutions. <b>2005</b> , 33, 155-64	160
1121	Nimesulide [Actions and Uses. <b>2005</b> ,	9
1120	Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. <b>2005</b> , 40, 1095-101	107
1119	Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. <b>2005</b> , 129, 512-21	681
1118	[Autoimmune hepatitis after risperidone-induced cholestatic hepatitis]. <b>2005</b> , 28, 135-6	1
1117	[Toxic hepatitis after flutamide treatment]. <b>2005</b> , 36, 112	

1116	Hepatic findings in long-term clinical trials of ximelagatran. <b>2005</b> , 28, 351-70		134
1115	Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period. <b>2005</b> , 129, 512-521		554
1114	The role of pathology in the identification of drug-induced hepatic toxicity. <b>2006</b> , 2, 241-7		10
1113	Drug-related hepatotoxicity. <b>2006</b> , 354, 731-9		736
1112	Case report: fulminant hepatic failure involving duloxetine hydrochloride. <b>2006</b> , 4, 912-7		28
1111	Suspected drug-induced liver fatalities reported to the WHO database. <b>2006</b> , 38, 33-8		109
1110	Atorvastatin associated liver disease. <b>2006</b> , 38, 772-7		58
1109	Hepatotoxicity associated with acarbose therapy. <b>2006</b> , 40, 151-4		51
1108	A new method for assessing drug causation provided agreement with experts' judgment. <i>Journal of Clinical Epidemiology</i> , <b>2006</b> , 59, 308-14	5:7	40
1107	Clinical characteristics and prognostic markers in disulfiram-induced liver injury. <b>2006</b> , 44, 791-7		60
1106	Severe liver injury after initiating therapy with atomoxetine in two children. <b>2006</b> , 148, 831-4		46
1105	Rofecoxib-induced hepatotoxicity: a forgotten complication of the coxibs. <b>2006</b> , 20, 351-5		13
1104	Hepatitis caused by the herbal remedy <i>Teucrium polium</i> L. <b>2006</b> , 18, 681-3		37
1103	Acute hepatitis due to shen-min: a herbal product derived from <i>Polygonum multiflorum</i> . <b>2006</b> , 40, 629-32		59
1102	The diagnosis of drug-induced liver disease. <b>2006</b> , 1, 207-17		5
1101	CD8-positive T cell-induced liver damage was found in a patient with polymyositis. <b>2006</b> , 45, 1059-63		2
1100	A recovery case of acute-onset autoimmune hepatitis presenting as fulminant hepatic failure [corrected], who received living donor-liver transplantation. <b>2006</b> , 45, 1217-20		3
1099	'Hy's law,' the 'Rezulin Rule,' and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective. <b>2006</b> , 15, 221-9		63

1098	How can 'Hy's law' help the clinician?. <b>2006</b> , 15, 235-9	34
1097	High expression of eosinophil chemoattractant ecalectin/galectin-9 in drug-induced liver injury. <b>2006</b> , 26, 106-15	11
1096	Traditional Chinese medicine causing hepatotoxicity in patients with chronic hepatitis B infection: a 1-year prospective study. <b>2006</b> , 24, 1179-86	84
1095	Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. <b>2006</b> , 24, 1187-95	149
1094	Drug-induced liver injury: Hy's rule revisited. <b>2006</b> , 79, 521-8	81
1093	[Adverse drugs reactions: diagnosis and assessment]. <b>2006</b> , 27, 6-12	7
1092	[Morphology of drug induced liver damage]. <b>2006</b> , 27, 175-81	6
1091	Toxicité hépatique des médicaments: le point de vue du clinicien... et du pathologiste. <b>2006</b> , 36, 315-323	
1090	Drug-induced liver injury: summary of a single topic clinical research conference. <b>2006</b> , 43, 618-31	227
1089	Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. <b>2006</b> , 44, 1581-8	223
1088	Fulminant hepatic failure associated with the use of black cohosh: a case report. <b>2006</b> , 12, 989-92	74
1087	Incidence of dimethylacetamide induced hepatic injury among new employees in a cohort of elastane fibre workers. <b>2006</b> , 63, 688-93	12
1086	Atomoxetine-induced hepatitis in a child. <b>2007</b> , 45, 51-5	22
1085	Drug-induced acute cholestatic liver damage in a patient with mutation of UGT1A1. <b>2007</b> , 4, 403-8	16
1084	[Toxic liver disease due to drugs, herbs and dietary supplements: diagnostic approaches]. <b>2007</b> , 45, 195-208	5
1083	Tobramycin-induced hepatotoxicity. <b>2007</b> , 41, 2061-5	11
1082	Drug Allergic Liver Injury. <b>2007</b> , 278-294	
1081	Association between physical restraint and drug-induced liver injury. <b>2007</b> , 56, 180-4	9

1080	Drug-Induced Liver Disease. <b>2007</b> , 1-11	2
1079	Drug-Induced Liver Disease. 478-512	2
1078	MRP2 haplotypes confer differential susceptibility to toxic liver injury. <b>2007</b> , 17, 403-15	119
1077	Terbinafine-induced acute autoimmune hepatitis in the setting of hepatitis B virus infection. <b>2007</b> , 41, 880-4	25
1076	Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. <b>2007</b> , 47, 128-34	170
1075	Serious adverse liver reactions associated with herbal weight-loss supplements. <b>2007</b> , 47, 295-7; author reply 297-8	38
1074	[Acute hepatitis associated with mefloquine therapy]. <b>2007</b> , 30, 102-3	1
1073	Oral aloe vera-induced hepatitis. <b>2007</b> , 41, 1740-3	65
1072	Herbal hepatotoxicity. <b>2007</b> , 11, 577-96, vii	112
1071	Clinical hepatotoxicity. Regulation and treatment with inducers of transport and cofactors. <b>2007</b> , 4, 895-910	21
1070	Antidepressant-induced liver injury. <b>2007</b> , 41, 1201-11	66
1069	[Chlorpromazine-induced cholestatic hepatitis in intractable hiccups]. <b>2007</b> , 30, 103	2
1068	Drug-induced liver injury. <b>2007</b> , 30, 277-94	215
1067	Guidelines for submitting adverse event reports for publication. <b>2007</b> , 30, 367-73	88
1066	Dimethylacetamide-induced hepatic injuries among spandex fibre workers. <b>2007</b> , 45, 435-9	18
1065	Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. <b>2007</b> , 11, 477-505, v	101
1064	Diagnostic criteria of drug-induced liver injury. <b>2007</b> , 48, 207-209	4
1063	Clinical Analysis of Adverse Drug Reactions. <b>2007</b> , 389-402	2

1062	Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. <b>2007</b> , 13, 329-40	104
1061	Grand rounds: an outbreak of toxic hepatitis among industrial waste disposal workers. <b>2007</b> , 115, 107-12	7
1060	Validity study of DDW-J2004 scoring scale for drug-induced liver injury. <b>2007</b> , 48, 219-226	11
1059	Black Cohosh and Climacteric Symptoms: Growing Knowledge about the Efficacy and Safety. <b>2007</b> , 2, 1934578X0700201	2
1058	Drug induced liver injury. 247-270	
1057	Guidelines for submitting adverse event reports for publication. <b>2007</b> , 16, 581-7	61
1056	Two cases of severe liver injury possibly related to 5-fluorouracil and calcium folinate. <b>2007</b> , 37, 344-5	2
1055	Review article: drug hepatotoxicity. <b>2007</b> , 25, 1135-51	161
1054	The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. <b>2007</b> , 25, 1411-21	115
1053	Long-term follow-up of patients with mild to moderate drug-induced liver injury. <b>2007</b> , 26, 79-85	48
1052	The role of hepatitis E virus testing in drug-induced liver injury. <b>2007</b> , 26, 1429-35	190
1051	Suspected cross-hepatotoxicity of flutamide and cyproterone acetate. <b>2007</b> , 27, 1144-7	18
1050	Monitoring liver safety in drug development: the GSK experience. <b>2007</b> , 49, 90-100	18
1049	[Liver and antiretrovirals: hepatotoxicity, steatosis and monitoring of patients with liver disease]. <b>2007</b> , 31, 895-905	1
1048	Idiosyncratic drug-induced liver injury: an overview. <b>2007</b> , 6, 673-84	137
1047	Inpatient admissions for drug-induced liver injury: results from a single center. <b>2008</b> , 53, 1977-82	24
1046	Nimesulide associated fulminant hepatic failure. <b>2008</b> , 17, 1108-12	16
1045	Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. <b>2008</b> , 47, 2003-9	294

1044	Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. <b>2008</b> , 48, 1175-83	134
1043	Fulminant hepatic failure associated with dicoumarol therapy. <b>1998</b> , 18, 67-9	7
1042	Assessment of drug-induced liver injury in clinical practice. <b>2008</b> , 22, 141-58	54
1041	Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. <b>2008</b> , 27, 780-9	112
1040	Late-onset celecoxib-induced combined hepato-nephrotoxicity. <b>2008</b> , 66, 150-1	12
1039	Causality assessment in hepatotoxicity by drugs and dietary supplements. <b>2008</b> , 66, 758-66	80
1038	Carbamazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: report of four cases and brief review. <b>2008</b> , 47, 853-60	87
1037	Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events. <b>2008</b> , 9, 48	30
1036	Practical guidelines for diagnosis and early management of drug-induced liver injury. <b>2008</b> , 14, 6774-85	123
1035	Methods for causality assessment of adverse drug reactions: a systematic review. <b>2008</b> , 31, 21-37	229
1034	Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder. <b>2008</b> , 31, 345-54	47
1033	Safety of green tea extracts : a systematic review by the US Pharmacopeia. <b>2008</b> , 31, 469-84	223
1032	[Toxic hepatitis due to <i>Camellia sinensis</i> ]. <b>2008</b> , 31, 402	4
1031	Successful treatment of fosinopril-induced severe cholestatic jaundice with plasma exchange. <b>2008</b> , 42, 1887-92	6
1030	Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. <b>2008</b> , 8, 29-33	152
1029	Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. <b>2008</b> , 135, 1924-34, 1934.e1-4	620
1028	Cholestatic hepatitis as a possible new side-effect of oxycodone: a case report. <b>2008</b> , 2, 140	5
1027	Analysis of IL-10, IL-4 and TNF-alpha polymorphisms in drug-induced liver injury (DILI) and its outcome. <b>2008</b> , 49, 107-14	63

1026	[Spanish version of the Severity of Dependence Scale (SDS)]. <b>2008</b> , 131, 797-8	7
1025	[Hepatotoxicity related to escitalopram]. <b>2008</b> , 131, 798	0
1024	Acute liver failure including acetaminophen overdose. <b>2008</b> , 92, 761-94, viii	147
1023	Dasatinib-induced acute hepatitis. <b>2008</b> , 49, 1630-2	18
1022	Drug-related hepatotoxicity and acute liver failure. <b>2008</b> , 47, 395-405	90
1021	Gastrointestinal plasmacytomas: a rare finding with important consequences. <b>2008</b> , 103, 2413-4	2
1020	Systematic Four-Quadrant Biopsy Detects Barrett's Dysplasia in More Patients Than Nonsystematic Biopsy: Reply. <b>2008</b> , 103, 2402-2403	
1019	The perplexing finding of esophageal eosinophilia. <b>2008</b> , 103, 2403	
1018	A rare complication of retrograde double-balloon enteroscopy: subcutaneous emphysema. <b>2008</b> , 103, 2409-10	2
1017	Onset of ulcerative colitis under treatment with adalimumab. <b>2008</b> , 103, 2410-2	7
1016	Conservative treatment of anastomotic leakage following low anterior resection. <b>2008</b> , 103, 2415-7	1
1015	Improved polyp detection: narrow-band imaging colonoscopy with a transparent retractable extension device. <b>2008</b> , 103, 2401; author reply 2401-2	1
1014	Does splenic vein thrombosis predict invasive malignancy in side-branch intraductal papillary mucinous neoplasm (IPMN)? <b>2008</b> , 103, 2412-3	
1013	Esophageal stent occlusion from a gastrostomy tube: balloon dilator-assisted endoscopic management. <b>2008</b> , 103, 2404-5	
1012	Increased number of targeted biopsies are better than systematic quadrantic biopsies at picking up Barrett's high grade dysplasia. <b>2008</b> , 103, 2402; author reply 2402-3	
1011	Response to Matsushita. <b>2008</b> , 103, 2401-2402	1
1010	Herbal does not at all mean innocuous: the sixth case of hepatotoxicity associated with morinda citrifolia (noni). <b>2008</b> , 103, 2406-7	38
1009	Endoscopically guided endotracheal intubation: a proposed airway management tool for the endoscopist. <b>2008</b> , 103, 2414-5	

1008 An unusual cause of colonic obstruction. **2008**, 103, 2407-9

1007 Idiosyncratic drug hepatotoxicity: a 2008 update. **2008**, 1, 261-76

14

1006 Diagnosis of jejunal diverticulitis by oral single-balloon enteroscopy. **2008**, 103, 2405-6

1005 Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis. **2008**, 42, 1112-7

24

1004 Late-onset rosiglitazone-associated acute liver failure in a patient with Hodgkin's lymphoma. **2008**, 42, 713-8

10

1003 Acute liver failure due to drugs. **2008**, 28, 175-87

51

1002 Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series. **2008**, 103, 111-9

186

1001 Comparative study of the usefulness of the drug-induced lymphocyte stimulation test and the leukocyte migration test in drug allergies. **2008**, 31, 299-304

27

1000 Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. **2008**, 20, 1182-93

104

999 Initially obscure hepatotoxicity attributed to sildenafil. **2008**, 20, 710-2

8

998 Drug-Induced Liver Disease (DILI). 174-194

997 United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity. **2008**, 15, 628-38

121

996 Acute drug-induced hepatitis caused by albendazole. **2008**, 23, 903-5

29

995 Acute hepatitis in a patient given propofol during colonoscopy. **2009**, 102, 333-4

9

994 Drug-induced liver injury: is it somehow foreseeable?. **2009**, 15, 2817-33

98

993 Drug-induced liver injury due to "natural products" used for weight loss: a case report. **2009**, 15, 2414-7

40

992 Hepatotoxicity by drugs and dietary supplements: safety perspectives on clinical and regulatory issues. **2009**, 8, 184-195

17

991 Severe hepatotoxicity by Indian Ayurvedic herbal products: A structured causality assessment. **2009**, 8, 258-266

66

990	Rechallenge in drug-induced liver injury: the attractive hazard. <b>2009</b> , 8, 709-14	38
989	Sildenafil-induced severe cholestatic hepatotoxicity. <b>2009</b> , 104, 254-5	6
988	A case of rectal MALT lymphoma treated by endoscopic resection. <b>2009</b> , 104, 255-6	6
987	Probable enoxaparin-induced hepatotoxicity. <b>2009</b> , 66, 638-41	12
986	The natural history of drug-induced liver injury. <b>2009</b> , 29, 357-63	26
985	Herbal and dietary supplement hepatotoxicity. <b>2009</b> , 29, 373-82	77
984	Causality assessment in drug-induced liver injury. <b>2009</b> , 29, 348-56	28
983	Acute hepatic injury associated with varenicline in a patient with underlying liver disease. <b>2009</b> , 43, 1539-43	8
982	Autoimmune Hepatitis Induced by Interferon Beta Therapy in a Patient with Multiple Sclerosis: A Case Report. <b>2009</b> , 25, 374-377	
981	Hepatitis after intravenous injection of sublingual buprenorphine in acute hepatitis C carriers: report of two cases of disappearance of viral replication after acute hepatitis. <b>2009</b> , 43, 973-7	24
980	Erlotinib-induced hepatitis complicated by fatal lactic acidosis in an elderly man with lung cancer. <b>2009</b> , 43, 542-5	18
979	How safe is the use of thiazolidinediones in clinical practice?. <b>2009</b> , 8, 15-32	112
978	Fatal liver failure in a patient on acetaminophen treated with sunitinib malate and levothyroxine. <b>2009</b> , 43, 761-6	33
977	Suspected hepatotoxicity by Cimicifugae racemosae rhizoma (black cohosh, root): critical analysis and structured causality assessment. <b>2009</b> , 16, 72-84	47
976	Drug-induced liver injury following positive drug rechallenge. <b>2009</b> , 54, 84-90	45
975	Fatal acute hepatitis after sequential treatment with levofloxacin, doxycycline, and naproxen in a patient presenting with acute Mycoplasma pneumoniae infection. <b>2009</b> , 31, 1014-9	19
974	[Hepatotoxicity of drugs and chemicals]. <b>2009</b> , 33, 1136-46	19
973	Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases. <b>2009</b> , 49, 250-7	89

972	Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. <b>2009</b> , 49, 2001-9	221
971	Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing database. <b>2009</b> , 15, 719-29	82
970	Conjugated linoleic acid-induced toxic hepatitis: first case report. <b>2009</b> , 54, 1141-3	42
969	Granulomatous liver disease. <b>2009</b> , 11, 42-9	8
968	Hepatotoxicity from green tea: a review of the literature and two unpublished cases. <b>2009</b> , 65, 331-41	282
967	Evidence for immunological (allergic) mechanisms in a subgroup of patients with phenprocoumon-induced liver disease. <b>2009</b> , 65, 1195-201	5
966	Causality assessment of liver injury after chronic oral amiodarone intake. <b>2009</b> , 18, 291-300	9
965	Three cases of severe hepatic impairment caused by erlotinib. <b>2009</b> , 68, 464-7	10
964	HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. <b>2009</b> , 41, 816-9	818
963	Toxic hepatitis after consumption of traditional kava preparation. <b>2009</b> , 16, 55-6	21
962	Fatal liver injury associated with clopidogrel. <b>2010</b> , 24, 433-5	10
961	[Toxic hepatitis associated with the use of medroxyprogesterone]. <b>2009</b> , 32, 72-3	1
960	[Moxifloxacin and hepatic toxicity]. <b>2009</b> , 32, 719-20	2
959	Suspected black cohosh hepatotoxicity--challenges and pitfalls of causality assessment. <b>2009</b> , 63, 302-14	51
958	Kava hepatotoxicity: comparison of aqueous, ethanolic, acetonic kava extracts and kava-herbs mixtures. <b>2009</b> , 123, 378-84	57
957	The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. <b>2009</b> , 50, 511-7	107
956	Acute hepatitis due to brivudin: a case report. <b>2009</b> , 51, 967-9	2
955	[Acute liver failure due to a treatment by nimesulide]. <b>2009</b> , 28, 262-3	0

954	Kava hepatotoxicity: regulatory data selection and causality assessment. <b>2009</b> , 41, 891-901	23
953	How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. <b>2009</b> , 104, 356-62	86
952	Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. <b>2009</b> , 32, 55-68	308
951	Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. <b>2009</b> , 32, 787-800	35
950	Histological patterns in drug-induced liver disease. <b>2009</b> , 62, 481-92	201
949	Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population. <b>2009</b> , 10, 1433-45	57
948	Diagnosis, management and prevention of drug-induced liver injury. <b>2009</b> , 58, 1555-64	122
947	Human drug hepatotoxicity: a contemporary clinical perspective. <b>2009</b> , 5, 463-73	36
946	Hepatotoxicity during low-dose flutamide treatment for hirsutism. <b>2009</b> , 25, 419-22	13
945	Evidence-Based Liver Chemistry Monitoring in Drug Development. <b>2009</b> , 23, 149-158	3
944	Liver injury associated with the use of Fructus Psoraleae (Bol-gol-zhee or Bu-gu-zhi) and its related proprietary medicine. <b>2009</b> , 47, 683-5	67
943	Reduced sexual desire in women. <b>2009</b> , 339, b2371	1
942	Recent status of drug-induced liver injury. <b>2009</b> , 39, 1-6	29
941	Present status of drug-induced liver injury (DILI) in Japan: Is a proposed diagnostic scale useful?. <b>2009</b> , 39, 949-50	0
940	Black cohosh hepatotoxicity: quantitative causality evaluation in nine suspected cases. <b>2009</b> , 16, 956-65	30
939	Guidelines for submitting adverse event reports for publication. <b>2009</b> , 64, 289-94	21
938	Letters to the Editor. <b>2009</b> , 16, 214	9
937	Black cohosh and suspected hepatotoxicity: inconsistencies, confounding variables, and prospective use of a diagnostic causality algorithm. A critical review. <b>2010</b> , 17, 426-40	62

936	Drug-Induced Cholestatic Liver Injury. <b>2010</b> , 15, 91-95	
935	Drug-Induced Liver Injury. <b>2010</b> , 235-242	
934	Corticosteroid therapy in a case of severe cholestatic hepatitis associated with amoxicillin-clavulanate. <b>2010</b> , 6, 420-3	13
933	[Metformin-associated hepatotoxicity]. <b>2010</b> , 34, 483-7	3
932	Acute hepatitis associated with the use of levofloxacin. <b>2010</b> , 32, 1733-7	15
931	The evaluation of drug rechallenge: the casopitant Phase III program. <b>2010</b> , 58, 539-43	3
930	Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. <b>2010</b> , 51, 2117-26	239
929	Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. <b>2010</b> , 52, 730-42	206
928	Pharmacogenetics of drug-induced liver injury. <b>2010</b> , 52, 748-61	118
927	Mitochondrial and immunoallergic injury increase risk of positive drug rechallenge after drug-induced liver injury: a systematic review. <b>2010</b> , 52, 2216-22	25
926	Critères d'imputabilité des effets indésirables des médicaments. <b>2010</b> , 77, 173-175	4
925	Acute-on-chronic liver failure due to thiamazole in a patient with hyperthyroidism and trilogy of Fallot: case report. <b>2010</b> , 10, 93	9
924	Increased risk of hospitalization for acute hepatitis in patients with previous exposure to NSAIDs. <b>2010</b> , 19, 708-14	32
923	A safety grading scale to support dose escalation and define stopping rules for healthy subject first-entry-into-man studies: some points to consider from the French Club Phase I working group. <b>2010</b> , 70, 736-48	18
922	The predictors of complications in patients with drug-induced liver injury caused by antimicrobial agents. <b>2010</b> , 31, 1200-7	15
921	Review article: drug-induced liver injury in clinical practice. <b>2010</b> , 32, 3-13	94
920	Kava hepatotoxicity: comparative study of two structured quantitative methods for causality assessment. <b>2010</b> , 35, 545-63	26
919	Kava hepatotoxicity. A clinical review. <b>2010</b> , 9, 251-265	94

918	Occupational hepatic disorders in Korea. <b>2010</b> , 25, S36-40	8
917	Guidelines for Submitting Adverse Event Reports for Publication. <b>2010</b> , 15, 107-114	
916	Fulminant hepatitis possibly related to pizotifen therapy. <b>2010</b> , 44, 1348-9	1
915	Discrepancy between clinical course and drug-induced lymphocyte stimulation tests in a case of saireito-induced liver injury accompanied by Sjögren syndrome. <b>2010</b> , 16, 501-5	10
914	Hepatotoxicity due to hydroxycut: a case series. <b>2010</b> , 105, 1561-6	96
913	Comment: Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain. <b>2010</b> , 44, 1349-50; author reply 1350-1	
912	Cytolytic hepatitis possibly related to levonorgestrel/ethinylestradiol oral contraceptive use: 2 case reports. <b>2010</b> , 44, 2035-7	10
911	Antibiotic-induced liver toxicity: mechanisms, clinical features and causality assessment. <b>2010</b> , 5, 212-22	21
910	Important elements for the diagnosis of drug-induced liver injury. <b>2010</b> , 8, 463-70	114
909	Clinical course and outcomes of drug-induced liver injury: nimesulide as the first implicated medication. <b>2010</b> , 42, 143-8	23
908	Adverse events, toxicity and post-mortem data on duloxetine: case reports and literature survey. <b>2010</b> , 17, 175-85	9
907	Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. <b>2010</b> , 33, 503-22	110
906	Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. <b>2010</b> , 53, 1049-53	114
905	AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the effective health-care program. <i>Journal of Clinical Epidemiology</i> , <b>2010</b> , 63, 502-12	5-7 123
904	[Topiramate-induced acute hepatitis]. <b>2010</b> , 33, 148-9	1
903	[Efalizumab-induced autoimmune hepatitis]. <b>2010</b> , 33, 69-70	5
902	[Aceclofenac-induced acute cholestatic lesion]. <b>2010</b> , 33, 417-8	1
901	[Acute toxic hepatitis secondary to a single dose of bupropion]. <b>2010</b> , 33, 547-9	4

900	Detective work in drug-induced liver injury: sometimes it is all about interviewing the right witness. <b>2010</b> , 8, 635-7	12
899	Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. <b>2010</b> , 105, 2396-404	147
898	Azithromycin-induced liver injury. <b>2010</b> , 67, 810-4	29
897	Hepatotoxicity associated with metformin therapy in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease. <b>2010</b> , 44, 1655-9	32
896	Hepatic safety of antibiotics used in primary care. <b>2011</b> , 66, 1431-46	118
895	Drug-Induced Liver Disease. <b>2011</b> , 703-783	4
894	Clinical and histopathologic features of fluoroquinolone-induced liver injury. <b>2011</b> , 9, 517-523.e3	93
893	Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. <b>2011</b> , 141, 338-47	359
892	Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. <b>2011</b> , 141, 1665-72.e1-9	256
891	Hepatotoxicity related to antirheumatic drugs. <b>2011</b> , 7, 139-50	106
890	Liver Injury Due to Drugs and Herbal Agents. <b>2011</b> , 311-352	
889	Steroid and ursodesoxycholic Acid combination therapy in severe drug-induced liver injury. <b>2011</b> , 84, 54-9	60
888	Safety of low-dose oral dantrolene sodium on hepatic function. <b>2011</b> , 92, 1359-63	12
887	[Recurrent hepatocellular lesion due to alfuzosin]. <b>2011</b> , 34, 125-7	2
886	[Acute cholestatic hepatitis associated with levofloxacin]. <b>2011</b> , 34, 369-70	4
885	[Amoxicillin-induced cholestatic hepatitis]. <b>2011</b> , 34, 474-7	2
884	Hepatic sinusoidal obstruction syndrome associated with consumption of <i>Gynura segetum</i> . <b>2011</b> , 54, 666-73	187
883	Causality assessment methods in drug induced liver injury: strengths and weaknesses. <b>2011</b> , 55, 683-691	130

- 882 Do the national survey results reflect the state of drug-induced liver injury in a single local city in which there is no hospital having Members of the Board of Councilors of the Japan Society of Hepatology? Results of a questionnaire survey conducted in a local city. **2011**, 41, 225-32
- 881 Hepatopatías tóxicas farmacológicas y no farmacológicas. **2011**, 15, 1-10
- 880 Herb induced liver injury presumably caused by black cohosh: A survey of initially purported cases and herbal quality specifications. **2011**, 10, 249-259 41
- 879 Cutaneous Adverse Reactions to Fluoroquinolones. **2011**, 22, 155-160 12
- 878 Causality assessment of cutaneous adverse drug reactions. **2011**, 23, 432-8 11
- 877 Jaundiced after a party. **2011**, 342, d3441
- 876 Correlation versus causation? Pharmacovigilance of the analgesic flupirtine exemplifies the need for refined spontaneous ADR reporting. **2011**, 6, e25221 27
- 875 Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool. **2011**, 6, e28096 110
- 874 Acute liver failure after recommended doses of acetaminophen in patients with myopathies. **2011**, 39, 678-82 17
- 873 Suspected black cohosh hepatotoxicity: no evidence by meta-analysis of randomized controlled clinical trials for isopropanolic black cohosh extract. **2011**, 18, 366-75 55
- 872 Duloxetine for depression and the incidence of hepatic events in adults. **2011**, 31, 517-22 8
- 871 Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study. **2011**, 53, 182-9 59
- 870 Hépatopathies toxiques médicamenteuses et non médicamenteuses: généralités. **2011**, 6, 1-10
- 869 Hépatopathies toxiques médicamenteuses et non médicamenteuses. **2011**, 6, 1-10
- 868 Overview: Adverse Drug Reactions. 27-37
- 867 Review of liver injury associated with dietary supplements. **2011**, 31, 595-605 75
- 866 Case definition and phenotype standardization in drug-induced liver injury. **2011**, 89, 806-15 563
- 865 Regulatory causality evaluation methods applied in kava hepatotoxicity: are they appropriate?. **2011**, 59, 1-7 36

864	Herbal hepatotoxicity by Greater Celandine ( <i>Chelidonium majus</i> ): causality assessment of 22 spontaneous reports. <b>2011</b> , 61, 282-91	47
863	Drug-induced autoimmune-like hepatitis. <b>2011</b> , 56, 958-76	178
862	Pathology of flupirtine-induced liver injury: a histological and clinical study of six cases. <b>2011</b> , 458, 709-16	28
861	Liver enzyme abnormalities in systemic lupus erythematosus: a focus on toxic hepatitis. <b>2011</b> , 31, 79-84	27
860	Severe cholestatic liver failure associated with gemcitabine adjuvant monotherapy for pancreatic cancer. <b>2011</b> , 4, 391-5	2
859	Anastrozole-related acute hepatitis with autoimmune features: a case report. <b>2011</b> , 11, 32	20
858	Paracetamol in therapeutic dosages and acute liver injury: causality assessment in a prospective case series. <b>2011</b> , 11, 80	37
857	Consistency between causality assessments obtained with two scales and their agreement with clinical judgments in hepatotoxicity. <b>2011</b> , 20, 272-85	15
856	Drug induced hepatotoxicity: data from the Serbian pharmacovigilance database. <b>2011</b> , 20, 416-23	6
855	Spontaneous reports of assumed herbal hepatotoxicity by black cohosh: is the liver-unspecific Naranjo scale precise enough to ascertain causality?. <b>2011</b> , 20, 567-82	38
854	Drug-Induced liver injury with hypersensitivity features has a better outcome: a single-center experience of 39 children and adolescents. <b>2011</b> , 54, 1344-50	54
853	Association of N-acetyltransferase-2 genotypes and anti-tuberculosis induced liver injury; first case-controlled study from Iran. <b>2011</b> , 6, 17-22	18
852	Causality assessment of herb-induced liver injury using multidisciplinary approach and Roussel Uclaf Causality Assessment Method (RUCAM). <b>2011</b> , 49, 34-9	28
851	Mirtazapine-induced hepatocellular-type liver injury. <b>2011</b> , 45, 825-6	5
850	Pregabalin-induced hepatotoxicity. <b>2011</b> , 45, e32	29
849	A Case of Drug-Induced Hepatitis due to Lenalidomide. <b>2011</b> , 5, 217-22	6
848	Diagnosis: Liver biopsy differentiates DILI from autoimmune hepatitis. <b>2011</b> , 8, 540-2	8
847	HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. <b>2011</b> , 29, 667-73	223

846	Severe hepatotoxicity and probable hepatorenal syndrome associated with sulfadiazine. <b>2011</b> , 68, 888-92	12
845	Cholestatic hepatitis with intravenous ceftriaxone. <b>2011</b> , 43, 474-5	5
844	Hepatotoxicity of Herbal Preparations. <b>2012</b> , 462-475	4
843	[Diagnostic approach in cases of herbal hepatotoxicity]. <b>2012</b> , 50, 776-91	
842	SLCO1B1 *15 haplotype is associated with rifampin-induced liver injury. <b>2012</b> , 6, 75-82	25
841	Metformin-induced hepatotoxicity. <b>2012</b> , 35, e21	32
840	Acute and chronic viral hepatitis. <b>2012</b> , 361-401	5
839	Amoxicillin-clavulanic acid hepatotoxicity in children. <b>2012</b> , 55, 663-7	8
838	Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. <b>2012</b> , 22, 784-95	96
837	Suspected Greater Celandine hepatotoxicity: liver-specific causality evaluation of published case reports from Europe. <b>2012</b> , 24, 270-80	38
836	Un caso de hepatopatía tóxica. <b>2012</b> , 11, 624.e1-624.e4	
835	Herbal hepatotoxicity: a tabular compilation of reported cases. <b>2012</b> , 32, 1543-56	95
834	Hepatitis E masquerading as drug-induced liver injury. <b>2012</b> , 56, 2420-3	25
833	Comparison of three pharmacovigilance algorithms in the ICU setting: a retrospective and prospective evaluation of ADRs. <b>2012</b> , 35, 645-53	24
832	Abstracts. <b>2012</b> , 35, 877-970	2
831	Suspected Herbal Hepatotoxicity. <b>2012</b> , 35, 1091-1097	28
830	Toxic hepatitis in a group of 20 male body-builders taking dietary supplements. <b>2012</b> , 50, 3826-32	39
829	Tobacco consumption is a reversible risk factor associated with reduced successful treatment outcomes of anti-tuberculosis therapy. <b>2012</b> , 16, e130-5	18

828	Suspected herbal hepatotoxicity: The pharmacovigilance dilemma with disputed and obsolete evaluation methods. <b>2012</b> , 64, 343-344		10
827	Un caso di epatite colestatica da ticlopidina: descrizione del caso e revisione della letteratura. <b>2012</b> , 6, 216-221		0
826	Acute hepatitis induced by fosfomycin: A case report and review of the literature. <b>2012</b> , 19, 263-266		2
825	[Methimazole-induced liver injury]. <b>2012</b> , 36, 431-2		0
824	Kausalitätsbewertung von Leberschäden [Notwendige und wünschenswerte Daten]. <b>2012</b> , 62, 108-114		
823	Alanine aminotransferase: a clinical and regulatory tool for detecting liver injury-past, present, and future. <b>2012</b> , 92, 332-9		98
822	Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. <b>2012</b> , 56, 374-80		214
821	An Update on Drug-induced Liver Injury. <b>2012</b> , 2, 247-59		79
820	An updated method improved the assessment of adverse drug reaction in routine pharmacovigilance. <i>Journal of Clinical Epidemiology</i> , <b>2012</b> , 65, 1069-77	5:7	21
819	A prospective study on the safety of herbal medicines, used alone or with conventional medicines. <b>2012</b> , 143, 884-8		38
818	Etifoxine-induced acute hepatitis: a case series. <b>2012</b> , 36, e85-8		10
817	Thalidomide-induced acute cholestatic hepatitis: case report and review of the literature. <b>2012</b> , 35, 560-6		11
816	Hospital admissions for drug-induced liver injury: clinical features, therapy, and outcomes. <b>2012</b> , 64, 77-83		29
815	Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma. <b>2012</b> , 12, 590		23
814	Fulminant hepatic failure in association with quetiapine: a case report. <b>2012</b> , 6, 418		9
813	Hepatotoxicity associated with statins. <b>2012</b> , 11, 418-420		3
812	Greater Celandine hepatotoxicity: a clinical review. <b>2012</b> , 11, 838-848		34
811	Initially purported hepatotoxicity by Pelargonium sidoides: the dilemma of pharmacovigilance and proposals for improvement. <b>2012</b> , 11, 500-512		26

810	Ticlopidine-induced cholestatic hepatitis: A case report and review of the literature. <b>2012</b> ,	
809	Repeated exposure to modern volatile anaesthetics may cause chronic hepatitis as well as acute liver injury. <b>2012</b> , 2012,	10
808	Spontaneously reported hepatic adverse drug events in Korea: multicenter study. <b>2012</b> , 27, 268-73	25
807	Drug-induced liver injury: present and future. <b>2012</b> , 18, 249-57	92
806	Frequency, clinical presentation, and outcomes of drug-induced liver injury after liver transplantation. <b>2012</b> , 18, 803-10	28
805	USP suspected herbal hepatotoxicity: Quality of causality assessment is more important than quantity of counted cases, not vice versa. <b>2012</b> , 21, 336-338	11
804	Jaundice due to suspected statin hepatotoxicity: a case series. <b>2012</b> , 57, 1959-64	16
803	Clinical perspective: statins and the liver--harmful or helpful?. <b>2012</b> , 57, 1754-63	17
802	Fluoroquinolone-induced liver injury: three new cases and a review of the literature. <b>2012</b> , 68, 525-32	17
801	Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids. <b>2012</b> , 13, 33-9	84
800	Kava hepatotoxicity in traditional and modern use: the presumed Pacific kava paradox hypothesis revisited. <b>2012</b> , 73, 170-4	34
799	Accuracy and reproducibility of two scales in causality assessment of unexpected hepatotoxicity. <b>2012</b> , 37, 196-203	12
798	Adverse drug events in rheumatoid arthritis and osteoarthritis ambulatory patients. <b>2012</b> , 15, 315-21	9
797	Spontaneous reports of primarily suspected herbal hepatotoxicity by Pelargonium sidoides: was causality adequately ascertained?. <b>2012</b> , 63, 1-9	36
796	NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. <b>2013</b> , 69, 1091-101	143
795	Methodology for a multinational case-population study on liver toxicity risks with NSAIDs: the Study of Acute Liver Transplant (SALT). <b>2013</b> , 69, 605-16	13
794	Specific genetic polymorphisms of IL10-592 AA and IL10-819 TT genotypes lead to the key role for inducing docetaxel-induced liver injury in breast cancer patients. <b>2013</b> , 15, 331-4	16
793	Drug-induced liver injury associated with Agaricus blazei Murill which is very similar to autoimmune hepatitis. <b>2013</b> , 6, 139-44	8

792	Intentional rechallenge: does the benefit outweigh the risk?. <b>2013</b> , 36, 155-61	4
791	Severe immune-mediated drug-induced liver injury linked to ibandronate: a case report. <b>2013</b> , 59, 1139-42	11
790	Crizotinib-induced acute hepatitis: first case with relapse after reintroduction with reduced dose. <b>2013</b> , 37, e21-3	18
789	¿Curar o provocar?. <b>2013</b> , 20, 54-55	
788	Fatal liver failure in a patient treated with sunitinib for renal cell carcinoma. <b>2013</b> , 11, 70-2	8
787	Drug-induced steatohepatitis. <b>2013</b> , 17, 533-46, vii	49
786	Liver injury induced by herbal complementary and alternative medicine. <b>2013</b> , 17, 715-35, x	34
785	Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. <b>2013</b> , 17, 643-56, ix	35
784	Drug-induced liver injury after allogeneic bone marrow transplantation. <b>2013</b> , 98, 499-503	o
783	Drug-Induced Liver Injury Throughout the Drug Development Life Cycle: Where We Have Been, Where We are Now, and Where We are Headed. Perspectives of a Clinical Hepatologist. <b>2013</b> , 27, 165-191	14
782	Assess the evidence and prepare plan of action prior to intentional rechallenge with drugs suspected of causing an adverse reaction. <b>2013</b> , 29, 395-397	
781	CYP2C9 and ABCG2 polymorphisms as risk factors for developing adverse drug reactions in renal transplant patients taking fluvastatin: a case-control study. <b>2013</b> , 14, 1419-31	21
780	Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate. <b>2013</b> , 14, 63-73	17
779	Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury. <b>2013</b> , 28, 161-7	52
778	How to avoid being surprised by hepatotoxicity at the final stages of drug development and approval. <b>2013</b> , 17, 749-67, xi	17
777	Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. <b>2013</b> , 144, 1419-25, 1425.e1-3; quiz e19-20	504
776	Drug-induced cholestasis. <b>2013</b> , 17, 191-209	49
775	[Severe hepatitis in a patient with adult-onset Still's disease treated with anakinra]. <b>2013</b> , 34, 168-70	13

774	Herbal hepatotoxicity: a hidden epidemic. <b>2013</b> , 8, 13-22	43
773	Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury. <b>2013</b> , 58, 317-26	58
772	Cancer Chemotherapy. <b>2013</b> , 541-567	5
771	Drug-induced liver injury: Icelandic lessons. <b>2013</b> , 144, 1335-6	7
770	Evaluation of adverse drug reactions in medical intensive care units. <b>2013</b> , 69, 119-31	11
769	Causality of Drugs Involved in Acute Liver Failure Leading to Transplantation: Results from the Study of Acute Liver Transplant (SALT). <b>2013</b> , 36, 757-64	7
768	Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study. <b>2013</b> , 36, 135-44	76
767	Associations of gender and age with the reporting of drug-induced hepatic failure: data from the Vigibase. <b>2013</b> , 53, 435-43	11
766	Drug-Induced Liver Injury: Introduction and Overview. <b>2013</b> , 3-14	25
765	Causality Assessment. <b>2013</b> , 287-302	1
764	Hepatotoxicity of Psychotropic Drugs and Drugs of Abuse. <b>2013</b> , 443-462	8
763	Hepatotoxicity of Herbals and Dietary Supplements. <b>2013</b> , 631-657	9
762	Regulatory Perspectives. <b>2013</b> , 689-712	1
761	LiverTox. <b>2013</b> , 725-732	3
760	Correspondence. <b>2013</b> , 50, 1064-1068	6
759	[Hepatotoxicity due to drugs or natural products in children]. <b>2013</b> , 78, 248-59	5
758	Clinical and causality assessment in herbal hepatotoxicity. <b>2013</b> , 12, 339-66	49
757	Arzneimittelinduzierte Leberschäden. <b>2013</b> , 8, 448-450	

756	Trastuzumab-induced hepatotoxicity: a case report. <b>2013</b> , 8, 146-8	10
755	Safety of long-term isoniazid preventive therapy in children with HIV: a comparison of two dosing schedules. <b>2013</b> , 17, 26-31	9
754	[Pharmacovigilance and herbal hepatotoxicity: critical aspects and solutions]. <b>2013</b> , 138, 281-4	3
753	Drug-Induced Liver Injury Associated with Noni ( <i>Morinda citrifolia</i> ) Juice and Phenobarbital. <b>2013</b> , 7, 19-24	20
752	Cholestatic jaundice as a result of combination designer supplement ingestion. <b>2013</b> , 47, e33	9
751	Efficacy and safety evaluation of a large niacin therapeutic interchange program. <b>2013</b> , 47, 657-64	3
750	Herbal hepatotoxicity: suspected cases assessed for alternative causes. <b>2013</b> , 25, 1093-8	59
749	Drug-induced liver injury caused by adalimumab: a case report and review of the bibliography. <b>2013</b> , 2013, 406901	6
748	Drug-induced liver injury in the Australian setting. <b>2013</b> , 38, 115-20	17
747	Identifying 2 prenylflavanones as potential hepatotoxic compounds in the ethanol extract of <i>Sophora flavescens</i> . <b>2013</b> , 78, T1830-4	17
746	Clinical risk factors for adverse events in allopurinol users. <b>2013</b> , 53, 211-6	24
745	Characterizing phenotypes and outcomes of drug-associated liver injury using electronic medical record data. <b>2013</b> , 22, 190-8	24
744	Hepatotoxicity from anabolic androgenic steroids marketed as dietary supplements: contribution from ATP8B1/ABCB11 mutations?. <b>2013</b> , 33, 1266-70	38
743	Herbal hepatotoxicity: a critical review. <b>2013</b> , 75, 630-6	53
742	Association of CYP2C9*2 with bosentan-induced liver injury. <b>2013</b> , 94, 678-86	43
741	Elevated liver enzymes associated with dronedarone for atrial fibrillation. <b>2013</b> , 1, 2050313X13511600	
740	Safety and Tolerability of EPs 7630 in Clinical Trials. <b>2013</b> , 02,	1
739	Delayed Liver Function Impairment Secondary to Interferon $\beta$ 1a Use in Multiple Sclerosis. <b>2013</b> , 5, 130-4	3

738	Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy. <b>2013</b> , 4, 9-14	5
737	Herbal hepatotoxicity: challenges and pitfalls of causality assessment methods. <b>2013</b> , 19, 2864-82	49
736	Albendazole-induced granulomatous hepatitis: a case report. <b>2013</b> , 7, 201	22
735	HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. <b>2013</b> , 8, e68111	66
734	Liver physiology and liver diseases in the elderly. <b>2013</b> , 19, 8459-67	82
733	The influence of severe hypoalbuminemia on the half-life of vancomycin in elderly patients with methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia. <b>2013</b> , 8, 1323-8	17
732	Herbalife hepatotoxicity: Evaluation of cases with positive reexposure tests. <b>2013</b> , 5, 353-63	32
731	Herbal hepatotoxicity and WHO global introspection method. <b>2013</b> , 12, 11-21	19
730	Chelidonium majus-Induced Acute Hepatitis. <b>2014</b> , 37, 60	5
729	Traditional Chinese Medicine Induced Liver Injury. <b>2014</b> , 2, 80-94	41
728	Drug and herb induced liver injury: Council for International Organizations of Medical Sciences scale for causality assessment. <b>2014</b> , 6, 17-32	55
727	Multicenter study of trimethoprim/sulfamethoxazole-related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumonia. <b>2014</b> , 9, e106141	23
726	Hepatic sinusoidal obstruction syndrome caused by herbal medicine: CT and MRI features. <b>2014</b> , 15, 218-25	55
725	Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. <b>2014</b> , 13, 231-239	25
724	Acute hepatitis after starting pinaverium bromide in a patient taking mirtazapine. <b>2014</b> , 2014,	0
723	Drug induced liver injury: do we still need a routine liver biopsy for diagnosis today?. <b>2014</b> , 13, 121-126	21
722	Drug induced liver injury: accuracy of diagnosis in published reports. <b>2014</b> , 13, 248-255	45
721	Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients. <b>2014</b> , 13, 1305-17	7

720	Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: current status and challenges. <b>2014</b> , 37 Suppl 1, S9-17	71
719	How We Assess Causality. <b>2014</b> , 319-330	1
718	A case of anastrozole-related drug-induced autoimmune hepatitis. <b>2014</b> , 7, 414-7	11
717	MicroRNAs as potential circulating biomarkers of drug-induced liver injury: key current and future issues for translation to humans. <b>2014</b> , 7, 349-62	41
716	Hepatotoxicity induced by herbal and dietary supplements. <b>2014</b> , 34, 172-93	69
715	Severe Aplastic Anemia Following Acute Hepatitis from Toxic Liver Injury: Literature Review and Case Report of a Successful Outcome. <b>2014</b> , 2014, 216570	9
714	Acute hepatic injury with atorvastatin: an unusual occurrence. <b>2014</b> , 46, 343-4	1
713	Autoimmune hepatitis as an adverse effect of long-term methotrexate therapy. <b>2014</b> , 46, 649-50	4
712	Causality assessment: Which is best-expert opinion or RUCAM?. <b>2014</b> , 4, 4-8	15
711	Case report and cohort analysis of drug-induced liver injury associated with daptomycin. <b>2014</b> , 58, 4902-3	8
710	Drug-induced hepatotoxicity: incidence of abnormal liver function tests consistent with volatile anaesthetic hepatitis in trauma patients. <b>2014</b> , 34, 576-82	18
709	An automated causality assessment algorithm to detect drug-induced liver injury in electronic medical record data. <b>2014</b> , 23, 601-8	22
708	Risk of oral antifungal agent-induced liver injury in Taiwanese. <b>2014</b> , 77, 180-9	42
707	[Long-term-treatment of chronic pain patients with flupirtine--on hepatotoxicity and persistent effectiveness from 7 months to 22 years]. <b>2014</b> , 156 Suppl 4, 127-34	3
706	Liver safety assessment: required data elements and best practices for data collection and standardization in clinical trials. <b>2014</b> , 37 Suppl 1, S19-31	26
705	Causality assessment for suspected DILI during clinical phases of drug development. <b>2014</b> , 37 Suppl 1, S47-56	34
704	Azathioprine-Induced Rapid Hepatotoxicity. <b>2014</b> , 30, 18-20	3
703	Clinical features, diagnosis, and natural history of drug-induced liver injury. <b>2014</b> , 34, 134-44	48

702	Probable drug-induced liver injury associated with aliskiren: case report and review of adverse event reports from pharmacovigilance databases. <b>2014</b> , 71, 643-7	5
701	Hepatic Adverse Drug Reactions. <b>2014</b> , 539-555	
700	DILI and drug development: a regulatory perspective. <b>2014</b> , 34, 215-26	20
699	Liraglutide-induced autoimmune hepatitis. <b>2014</b> , 174, 984-7	15
698	Cholestasis in the Hospitalized Patient. <b>2014</b> , 201-228	
697	Alterations of canalicular ATP-binding cassette transporter expression in drug-induced liver injury. <b>2014</b> , 90, 81-8	15
696	A challenge for diagnosing acute liver injury with concomitant/sequential exposure to multiple drugs: can causality assessment scales be utilized to identify the offending drug?. <b>2014</b> , 2014, 156389	5
695	Response to "Acute Hepatitis Induced by Lyprinol, the Lipid Extract of the Green-Lipped Mussel ( <i>Perna canaliculus</i> ), in a Patient with Polyarthrosis". <b>2014</b> , 2014, 692043	
694	Fulminant hepatitis following crizotinib administration for ALK-positive non-small-cell lung carcinoma. <b>2014</b> , 44, 872-5	27
693	Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. <b>2014</b> , 59, 661-70	249
692	[Liver injury induced by linagliptine and sitagliptine: it' a class effect?]. <b>2014</b> , 214, 54-5	1
691	Development of predictive genetic tests for improving the safety of new medicines: the utilization of routinely collected electronic health records. <b>2014</b> , 19, 361-6	7
690	Herbal hepatotoxicity: analysis of cases with initially reported positive re-exposure tests. <b>2014</b> , 46, 264-9	30
689	Flupirtine-induced liver injury--seven cases from the Berlin Case-control Surveillance Study and review of the German spontaneous adverse drug reaction reporting database. <b>2014</b> , 70, 453-9	24
688	Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. <b>2014</b> , 60, 679-86	152
687	A detection algorithm for drug-induced liver injury in medical information databases using the Japanese diagnostic scale and its comparison with the Council for International Organizations of Medical Sciences/the Roussel Uclaf Causality Assessment Method scale. <b>2014</b> , 23, 984-8	23
686	Rivaroxaban postmarketing risk of liver injury. <b>2014</b> , 61, 293-300	48
685	Drug-induced liver injury. <b>2014</b> , 89, 95-106	247

684	XXXIV International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) 27-30 May 2014, Brussels, Belgium. <b>2014</b> , 52, 295-443	16
683	Idiosyncratic drug-induced liver injury: an update on the 2007 overview. <b>2014</b> , 13, 67-81	41
682	Correlation of antituberculosis drug-related liver injury and liver function monitoring: A 12-year experience of the Taiwan Drug Relief Foundation. <b>2014</b> , 22, 356-362	7
681	Ist bei einer Risikobeurteilung der Chinesischen Medizin die Einhaltung wissenschaftlicher Standards Berflßsig?. <b>2014</b> , 57, 16-19	2
680	Green tea extract and the risk of drug-induced liver injury. <b>2014</b> , 10, 1663-76	34
679	Outbreak of severe hepatitis linked to weight-loss supplement OxyELITE Pro. <b>2014</b> , 109, 1296-8	46
678	Carnitine for prevention of antituberculosis drug-induced hepatotoxicity: a randomized, clinical trial. <b>2014</b> , 29, 997-1004	20
677	Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. <b>2014</b> , 60, 1399-408	250
676	Cholestatic Liver Disease. <b>2014</b> ,	6
675	N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group. <b>2014</b> , 70, 1079-86	48
674	Hepatobiliary transporters in drug-induced cholestasis: a perspective on the current identifying tools. <b>2014</b> , 10, 581-97	26
673	Severe cholestatic jaundice after a single administration of ajmaline; a case report and review of the literature. <b>2014</b> , 14, 60	5
672	Drug-Induced Liver Injury. <b>2014</b> , 467-477	
671	Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. <b>2014</b> , 60, 872-84	52
670	Liver injury is common among chronic abusers of ketamine. <b>2014</b> , 12, 1759-62.e1	36
669	[Agomelatine: fulminant liver failure in a patient with fatty liver]. <b>2014</b> , 37, 92-4	9
668	Ketamine-related cholangiopathy: a retrospective study on clinical and imaging findings. <b>2014</b> , 39, 1241-6	9
667	ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <b>2014</b> , 109, 950-66; quiz 967	469

666	Concentrated green tea extract induces severe acute hepatitis in a 63-year-old woman--a case report with pharmaceutical analysis. <b>2014</b> , 155, 165-70	24
665	Adverse drug reactions in some African herbal medicine: literature review and stakeholders' interview. <b>2014</b> , 3, 126-132	37
664	Herbs and liver injury: a clinical perspective. <b>2014</b> , 12, 1069-76	20
663	Increasing impact of drug-induced liver injury. <b>2015</b> , 5, 136-138	7
662	[The cutting-edge of medicine: Diagnosis and treatment of drug-induced liver injury]. <b>2015</b> , 104, 991-7	0
661	Estimating heritability of drug-induced liver injury from common variants and implications for future study designs. <b>2014</b> , 4, 5762	4
660	N-acetylcysteine for non-paracetamol drug-induced liver injury: a systematic review protocol. <b>2015</b> , 4, 84	11
659	Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury. <b>2015</b> , 62, 887-99	67
658	Use of apixaban after development of suspected rivaroxaban-induced hepatic steatosis; a case report. <b>2015</b> , 26, 699-702	9
657	Drug-Induced Liver Injury After Soy Protein Supplement Use. <b>2015</b> , 2, 178-80	1
656	A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis. <b>2015</b> , 9, 5433-8	30
655	Drug Induced Steatohepatitis: An Uncommon Culprit of a Common Disease. <b>2015</b> , 2015, 168905	68
654	A Rare Case of Paclitaxel and/or Trastuzumab Induced Acute Hepatic Necrosis. <b>2015</b> , 2015, 825603	4
653	Traditional Chinese Medicine and herbal hepatotoxicity: a tabular compilation of reported cases. <b>2015</b> , 14, 7-19	55
652	Viral hepatitis prevalence in patients with active and latent tuberculosis. <b>2015</b> , 21, 8920-6	13
651	Liver Injury from Herbal, Dietary, and Weight Loss Supplements: a Review. <b>2015</b> , 3, 93-8	35
650	Chinese green tea and acute hepatitis: a rare yet recurring theme. <b>2015</b> , 2015,	3
649	Idiosyncratic Valproic Acid-Induced Hepatotoxicity in a Sickle Cell Patient. <b>2015</b> , 31, 43-46	1

648	A new animal model for Polygonum multiflorum Thunb-induced liver injury in rats and its potential mechanisms. <b>2015</b> , 4, 1085-1097	7
647	Hepatotoxicity of green tea: an update. <b>2015</b> , 89, 1175-91	108
646	Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients. <b>2015</b> , 51, 1293-302	40
645	Human leukocyte antigen genetic risk factors of drug-induced liver toxicology. <b>2015</b> , 11, 395-409	40
644	Successful Living-Donor Liver Transplantation for Cholestatic Liver Failure Induced by Allopurinol: Case Report. <b>2015</b> , 47, 2778-81	2
643	Drug-induced liver injury: an overview over the most critical compounds. <b>2015</b> , 89, 327-34	86
642	Agents and drugs: precautions in patients with cirrhosis. <b>2015</b> , 261-273	1
641	Hepatitis C direct antiviral drugs and hepatic decompensation in patients with advanced cirrhosis: culprit or innocent bystander?. <b>2015</b> , 60, 806-9	4
640	Herbal hepatotoxicity in traditional and modern medicine: actual key issues and new encouraging steps. <b>2015</b> , 6, 72	89
639	Secondary sclerosing cholangitis in patients with drug-induced liver injury. <b>2015</b> , 47, 502-7	30
638	Promiscuous T-cell responses to drugs and drug-haptens. <b>2015</b> , 136, 474-6.e8	31
637	How to Diagnose and Exclude Drug-Induced Liver Injury. <b>2015</b> , 33, 472-6	17
636	Preventing Drug-Induced Liver Injury: How Useful Are Animal Models?. <b>2015</b> , 33, 477-85	18
635	Drug-Induced Liver Injury Is a Major Risk for New Drugs. <b>2015</b> , 33, 458-63	9
634	The Art and Science of Diagnosing and Managing Drug-induced Liver Injury in 2015 and Beyond. <b>2015</b> , 13, 2173-89.e8	51
633	Drug-Induced Liver Injury. <b>2015</b> , 139, 876-87	100
632	Liver injury induced by herbal extracts containing mistletoe and kudzu. <b>2015</b> , 21, 180-5	9
631	[Toxic hepatocellular hepatitis due to labetalol]. <b>2015</b> , 38, 326-7	2

630	Liver injury in patients with DRESS: A clinical study of 72 cases. <b>2015</b> , 72, 984-91	36
629	[Mesalazine-induced acute hepatitis]. <b>2015</b> , 38, 302-3	2
628	The value of serum aspartate aminotransferase and gamma-glutamyl transpetidase as biomarkers in hepatotoxicity. <b>2015</b> , 35, 2474-82	31
627	Rivaroxaban-induced liver injury: Results from a venous thromboembolism registry. <b>2015</b> , 191, 265-6	11
626	Drug-induced liver injury: the dawn of biomarkers?. <b>2015</b> , 7, 34	34
625	Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. <b>2015</b> , 148, 1340-52.e7	466
624	Antitumor activity of a polypyridyl chelating ligand: in vitro and in vivo inhibition of glioma. <b>2015</b> , 7,	4
623	Acute liver failure during hepatitis C treatment with sofosbuvir and ledipasvir. <b>2015</b> , 47, 1091-2	4
622	Prevalence of genetic variants of keratins 8 and 18 in patients with drug-induced liver injury. <b>2015</b> , 13, 196	15
621	Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN). <b>2015</b> , 35, 1623-32	34
620	Is Making a Prognosis for Patients With Drug-induced Liver Injury Putting the Cart Before the Horse?. <b>2015</b> , 13, 2369-71	4
619	Evidence chain-based causality identification in herb-induced liver injury: exemplification of a well-known liver-restorative herb Polygonum multiflorum. <b>2015</b> , 9, 457-67	52
618	I-131 remnant ablation after thyroidectomy induced hepatotoxicity in a case of thyroid cancer. <b>2015</b> , 15, 56	6
617	Case Report and Literature Review: Quinacrine-induced Cholestatic Hepatitis in Undifferentiated Connective Tissue Disease. <b>2015</b> , 42, 1354-5	5
616	ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions: a case-control study. <b>2015</b> , 16, 803-15	23
615	Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system. <b>2015</b> , 148, 1353-61.e3	67
614	Herbal products and the liver: a review of adverse effects and mechanisms. <b>2015</b> , 148, 517-532.e3	77
613	Possible amlodipine-induced hepatotoxicity after stem cell transplant. <b>2015</b> , 49, 135-9	5

612	Risk of drug-induced liver injury from tumor necrosis factor antagonists. <b>2015</b> , 13, 602-8	82
611	Acute Hepatocellular Drug-Induced Liver Injury From Bupropion and Doxycycline. <b>2015</b> , 3, 66-8	15
610	Hepatotoxicity by Dietary Supplements: A Tabular Listing and Clinical Characteristics. <b>2016</b> , 17, 537	88
609	Research Advances on Hepatotoxicity of Herbal Medicines in China. <b>2016</b> , 2016, 7150391	26
608	Clopidogrel-Induced Severe Hepatitis: A Case Report and Literature Review. <b>2016</b> , 2016, 8068276	5
607	The Latin American DILI Registry Experience: A Successful Ongoing Collaborative Strategic Initiative. <b>2016</b> , 17, 313	40
606	Fatal Liver and Bone Marrow Toxicity by Combination Treatment of Dichloroacetate and Artesunate in a Glioblastoma Multiforme Patient: Case Report and Review of the Literature. <b>2016</b> , 6, 204	15
605	Drug-Induced Liver Injury Network Causality Assessment: Criteria and Experience in the United States. <b>2016</b> , 17, 201	48
604	The Honolulu Liver Disease Cluster at the Medical Center: Its Mysteries and Challenges. <b>2016</b> , 17, 476	24
603	Traditional Chinese Medicine (TCM) and Herbal Hepatotoxicity: RUCAM and the Role of Novel Diagnostic Biomarkers Such as MicroRNAs. <b>2016</b> , 3,	57
602	Genetic Polymorphisms of Glutathione S-Transferase P1 (GSTP1) and the Incidence of Anti-Tuberculosis Drug-Induced Hepatotoxicity. <b>2016</b> , 11, e0157478	16
601	Update on Advances in Research on Idiosyncratic Drug-Induced Liver Injury. <b>2016</b> , 8, 3-11	41
600	RUCAM in Drug and Herb Induced Liver Injury: The Update. <b>2015</b> , 17,	321
599	Acute liver failure associated with Garcinia cambogia use. <b>2016</b> , 15, 123-6	34
598	The mystery of the Hawaii liver disease cluster in summer 2013: A pragmatic and clinical approach to solve the problem. <b>2016</b> , 15, 91-109	29
597	Hepatic Failure in a Patient Receiving Itraconazole for Pulmonary Histoplasmosis-Case Report and Literature Review. <b>2016</b> , 23, e1215-21	4
596	HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury. <b>2016</b> , 26, 218-24	50
595	Hepatobiliary and pancreatic: Comparison between Chinese herbal medicine and Western medicine-induced liver injury of 1985 patients. <b>2016</b> , 31, 1476-82	66

594	Metformin as a Rare Cause of Drug-Induced Liver Injury, a Case Report and Literature Review. <b>2016</b> , 23, e315-7	8
593	Ginger for Prevention of Antituberculosis-induced Gastrointestinal Adverse Reactions Including Hepatotoxicity: A Randomized Pilot Clinical Trial. <b>2016</b> , 30, 1003-9	10
592	Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports. <b>2016</b> , 63, 590-603	144
591	The Effect of Hepatic Impairment on Outcomes in Phase I Clinical Trials in Cancer Subjects. <b>2016</b> , 22, 5472-5479	16
590	Drug-induced liver injury in the United States: A review of multi-ingredient supplements. <b>2016</b> , 7, 60-63	
589	Hepatology Clinical. <b>2016</b> , 31 Suppl 2, 89-120	0
588	Changes to protocol in the regulation of adverse drug reactions [historical and current European view. <b>2016</b> , 33, 49-58	1
587	Drug-induced liver injury. <b>2016</b> , 16, s104-s109	73
586	Drug-Induced Liver Injury. <b>2016</b> , 503-507	
585	Traditional Chinese Medicine and herbal hepatotoxicity: a tabular compilation of reported cases. <b>2016</b> , 59, 33-35	9
584	Severe liver injury due to a homemade flower pollen preparation in a patient with high CYP3A enzyme activity: a case report. <b>2016</b> , 72, 507-8	4
583	Hepatopatías de origen tóxico y farmacológico. <b>2016</b> , 12, 545-552	
582	Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. <b>2016</b> , 65, 532-42	82
581	Causality assessment in pharmacovigilance: The French method and its successive updates. <b>2016</b> , 71, 179-86	137
580	Clinical Features and Outcomes of Complementary and Alternative Medicine Induced Acute Liver Failure and Injury. <b>2016</b> , 111, 958-65	61
579	Imputabilidad en farmacovigilancia: de la método francesa originelle aux métodos reactualisés. <b>2016</b> , 71, 171-178	10
578	Diagnosis and Management of Drug-Induced Liver Injury (DILI) in Patients with Pre-Existing Liver Disease. <b>2016</b> , 39, 729-44	42
577	Rivaroxaban induced liver injury: A cholestatic pattern. <b>2016</b> , 216, 97-8	9

576	Drug-induced liver injury associated with Complementary and Alternative Medicine: a review of adverse event reports in an Asian community from 2009 to 2014. <b>2016</b> , 16, 192	26
575	Clinical characteristics of drug-induced liver injury and related risk factors. <b>2016</b> , 12, 2606-2616	31
574	Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen. <b>2016</b> , 9, 1493-1503	20
573	The risk of acute liver injury associated with the use of antibiotics--evaluating robustness of results in the pharmacoepidemiological research on outcomes of therapeutics by a European consortium (PROTECT) project. <b>2016</b> , 25 Suppl 1, 47-55	7
572	Methylprednisolone-induced liver injury: Case report and literature review. <b>2016</b> , 17, 55-62	18
571	N-acetylcysteine for non-paracetamol drug-induced liver injury: a systematic review. <b>2016</b> , 81, 1021-9	34
570	Validity of diagnostic codes and laboratory measurements to identify patients with idiopathic acute liver injury in a hospital database. <b>2016</b> , 25 Suppl 1, 21-8	11
569	Changes of four common non-infectious liver diseases for the hospitalized patients in Beijing 302 hospital from 2002 to 2013. <b>2016</b> , 54, 61-5	2
568	Cetirizine-induced hepatotoxicity: case series and review of the literature. <b>2018</b> , 6, 228-230	6
567	Chinese herbal medicine Tangshen Formula treatment of patients with type 2 diabetic kidney disease with macroalbuminuria: study protocol for a randomized controlled trial. <b>2016</b> , 17, 259	11
566	Mission Compromised? Drug-Induced Liver Injury From Prohormone Supplements Containing Anabolic-Androgenic Steroids in Two Deployed U.S. Service Members. <b>2016</b> , 181, e1169-71	3
565	Identification of a novel and severe pattern of efavirenz drug-induced liver injury in South Africa. <b>2016</b> , 30, 1483-5	15
564	Monocyte-derived hepatocyte-like cells for causality assessment of idiosyncratic drug-induced liver injury. <b>2016</b> , 65, 1555-63	33
563	A prospective study on the causes of notably raised alanine aminotransferase (ALT). <b>2016</b> , 51, 594-600	20
562	Adverse drug reactions and organ damage: The liver. <b>2016</b> , 28, 9-16	52
561	Predicting risk of adverse drug reactions in older adults. <b>2016</b> , 7, 11-22	145
560	An analysis of drug-induced liver injury, which showed histological findings similar to autoimmune hepatitis. <b>2016</b> , 51, 597-607	16
559	[Cholestatic hepatitis caused by amoxicillin-clavulanate of torpid evolution]. <b>2016</b> , 34, 139-40	2

558	Promising toxicological biomarkers for the diagnosis of liver injury types: Bile acid metabolic profiles and oxidative stress marker as screening tools in drug development. <b>2016</b> , 255, 74-82	15
557	Oxidative stress markers, secondary bile acids and sulfated bile acids classify the clinical liver injury type: Promising diagnostic biomarkers for cholestasis. <b>2016</b> , 255, 83-91	23
556	Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. <b>2016</b> , 64, 234-8	75
555	Clinical and histological features of idiosyncratic liver injury: Dilemma in diagnosis of autoimmune hepatitis. <b>2016</b> , 46, 277-91	9
554	Natural history and outcomes in drug-induced autoimmune hepatitis. <b>2016</b> , 46, E79-88	16
553	A Text Searching Tool to Identify Patients with Idiosyncratic Drug-Induced Liver Injury. <b>2017</b> , 62, 615-625	6
552	Toxic hepatitis after concomitant interferon beta and aloe vera treatment in a patient with multiple sclerosis: A case report. <b>2017</b> , 32, 546-547	3
551	Model-based contextualization of in vitro toxicity data quantitatively predicts in vivo drug response in patients. <b>2017</b> , 91, 865-883	14
550	Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system. <b>2017</b> , 83, 894-908	46
549	Toxicology of Herbal Products. <b>2017</b> ,	5
548	CSH guidelines for the diagnosis and treatment of drug-induced liver injury. <b>2017</b> , 11, 221-241	126
547	37th International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) 16-19 May 2017, Basel, Switzerland. <b>2017</b> , 55, 371-544	49
546	Overview of causality assessment in drug-induced liver injury. <b>2017</b> , 9, 29-33	7
545	Norethisterone Related Drug Induced Liver Injury: A Series of 3 Cases. <b>2017</b> , 7, 266-268	6
544	Analysis of Immunogenetic Factors in Idiosyncratic Drug-induced Liver Injury in the Pediatric Population. <b>2017</b> , 64, 742-747	9
543	Herbal Hepatotoxicity. <b>2017</b> , 271-305	
542	Methylprednisolone liver toxicity: A new case and a French regional pharmacovigilance survey. <b>2017</b> , 41, 497-501	14
541	Hepatitis due to Epstein-Barr virus and cytomegalovirus: clinical features and outcomes. <b>2017</b> , 52, 893-897	15

540	Aloe vera-induced acute liver injury: A case report and literature review. <b>2017</b> , 41, e39-e42	11
539	Drug-induced Liver Injury: The Hepatic Pathologist's Approach. <b>2017</b> , 46, 273-296	24
538	Preliminary Results of a Novel Algorithmic Method Aiming to Support Initial Causality Assessment of Routine Pharmacovigilance Case Reports for Medication-Induced Liver Injury: The PV-RUCAM. <b>2017</b> , 40, 715-727	10
537	Drug-Induced Autoimmune Hepatitis: Response to Corticosteroids and Lack of Relapse After Cessation of Steroids. <b>2017</b> , 15, 1635-1636	42
536	Hepatotoxicity of vascular endothelial growth factor receptor tyrosine kinase inhibitors: clinical practice and evidence. <b>2017</b> , 33, 395-402	
535	Features and Treatment of Dapsone-Induced Hepatitis, Based on Analysis of 44 Cases and Literature Review. <b>2017</b> , 15, 1805-1807	12
534	Drug-induced liver injury: recent advances in diagnosis and risk assessment. <b>2017</b> , 66, 1154-1164	250
533	Genome-Wide Association and Replication Study of Hepatotoxicity Induced by Antiretrovirals Alone or with Concomitant Anti-Tuberculosis Drugs. <b>2017</b> , 21, 207-216	11
532	Drug rechallenge following drug-induced liver injury. <b>2017</b> , 66, 646-654	32
531	Drug-induced liver injury: a cohort study on patients referred to the Danish transplant center over a five year period. <b>2017</b> , 52, 450-454	7
530	Severe Drug-Induced Liver Injury as an Adverse Drug Event of Antibiotics: A Case Report and Review of the Literature. <b>2017</b> , 62, 367-373	5
529	Drug-Induced Autoimmune Hepatitis following Treatment with Zoledronic Acid. <b>2017</b> , 11, 440-445	6
528	Genetic Polymorphisms of SLCO1B1, CYP2E1 and UGT1A1 and Susceptibility to Anti-Tuberculosis Drug-Induced Hepatotoxicity: A Chinese Population-Based Prospective Case-Control Study. <b>2017</b> , 37, 1125-1136	16
527	Frequency and pathological characteristics of drug-induced liver injury in a tertiary medical center. <b>2017</b> , 68, 92-98	8
526	Deferasirox associated with liver failure and death in a sickle cell anemia patient homozygous for the -1774delG polymorphism in the gene. <b>2017</b> , 5, 1218-1221	5
525	Causality assessment for liver injury attributable to dietary supplements. <b>2017</b> , 9, 60-62	
524	Idiosyncratic drug-induced liver injury: A short review. <b>2017</b> , 1, 494-500	17
523	Liver Toxicity From Solifenacin. <b>2017</b> , 24, e505-e506	1

522	Highlights of drug - and herb- induced liver injury in the literature from 2016: how best to translate new information into clinical practice?. <b>2017</b> , 13, 935-951	25
521	Drug-induced hepatitis: histologic clues to a difficult diagnosis. <b>2017</b> , 23, 559-562	1
520	Autoimmune Hepatitis-Induced by Drugs: a Challenging Diagnosis. <b>2017</b> , 16, 265-270	1
519	Drug-induced cholestasis. <b>2017</b> , 1, 726-735	59
518	Acute Liver Failure Induced by Anti-infectious Drugs: Causes and Management. <b>2017</b> , 16, 276-285	5
517	Toxic hepatitis after concomitant interferon beta and aloe vera treatment in a patient with multiple sclerosis: A case report. <b>2017</b> , 32, 546-547	1
516	Azathioprine and 6-Mercaptopurine-induced Liver Injury: Clinical Features and Outcomes. <b>2017</b> , 51, 63-69	42
515	Fragwürdige Pseudowissenschaft – Zur angeblichen Hepatotoxizität chinesischer Arzneimittel. <b>2017</b> , 32, 25-31	
514	Can causality assessment fulfill the new European definition of adverse drug reaction? A review of methods used in spontaneous reporting. <b>2017</b> , 123, 122-129	33
513	Quantification of the risk of liver injury associated with flucloxacillin: a UK population-based cohort study. <b>2017</b> , 72, 2636-2646	17
512	Drug-induced liver injury: Is chronic liver disease a risk factor and a clinical issue?. <b>2017</b> , 13, 425-438	35
511	Herbal and Dietary Supplement-Induced Liver Injury. <b>2017</b> , 21, 135-149	44
510	Management of Acute Hepatotoxicity Including Medical Agents and Liver Support Systems. <b>2017</b> , 21, 163-180	7
509	Drug-Induced Acute Liver Failure. <b>2017</b> , 21, 151-162	15
508	Valproate for agitation in critically ill patients: A retrospective study. <b>2017</b> , 37, 119-125	32
507	Drug-induced Hepatotoxicity. <b>2017</b> , 740-773	3
506	Incidence of Liver Injury Related to Kampo Medicine Containing Scutellaria Baicalensis at Our Clinic. <b>2017</b> , 68, 377-381	2
505	Prospective Indian Study of DILI with Confirmed Causality Using the Roussel Uclaf Causality Assessment Method (RUCAM): A report of Excellence. <b>2017</b> , 16, 324-325	13

504	A Case of Carbamazepine-induced Severe Cholestatic Hepatitis: Case Report and Review of Literature. <b>2017</b> , 39, 688-690	3
503	Allele Is Associated with Concomitant Anti-tuberculosis and Antiretroviral Drugs Induced Liver Toxicity in Ethiopians. <b>2017</b> , 8, 90	21
502	"Autoimmune(-Like)" Drug and Herb Induced Liver Injury: New Insights into Molecular Pathogenesis. <b>2017</b> , 18,	20
501	Liver Diseases in the Elderly. <b>2017</b> , 331-339	0
500	Hepatotoxicity of Herbal Supplements Mediated by Modulation of Cytochrome P450. <b>2017</b> , 18,	47
499	Revisiting the Metabolism and Bioactivation of Ketoconazole in Human and Mouse Using Liquid Chromatography-Mass Spectrometry-Based Metabolomics. <b>2017</b> , 18,	25
498	Drug Induced Liver Injury: Can Biomarkers Assist RUCAM in Causality Assessment?. <b>2017</b> , 18,	41
497	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): An Interplay among Drugs, Viruses, and Immune System. <b>2017</b> , 18,	105
496	Medicinal Plants from North and Central America and the Caribbean Considered Toxic for Humans: The Other Side of the Coin. <b>2017</b> , 2017, 9439868	12
495	Drug Induced Liver Injury at a Tertiary Hospital in India: Etiology, Clinical Features and Predictors of Mortality. <b>2017</b> , 16, 442-450	32
494	A Multicenter and Randomized Controlled Trial of Bicyclol in the Treatment of Statin-Induced Liver Injury. <b>2017</b> , 23, 5760-5766	20
493	Hepatic Damage by Natural Remedies. <b>2018</b> , 38, 21-40	24
492	Clinical outcomes, histopathological patterns, and chemical analysis of Ayurveda and herbal medicine associated with severe liver injury-A single-center experience from southern India. <b>2018</b> , 37, 9-17	34
491	Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study. <b>2018</b> , 47, 1213-1219	12
490	Drug-Induced Liver Injury: Why is the Roussel Uclaf Causality Assessment Method (RUCAM) Still Used 25 Years After Its Launch?. <b>2018</b> , 41, 735-743	50
489	Expanding our toolkit to better identify drug-induced liver injury in electronic medical records. <b>2018</b> , 38, 585-587	4
488	Drug induced liver injury with analysis of alternative causes as confounding variables. <b>2018</b> , 84, 1467-1477	33
487	Pharmacoeconomics of three Therapeutic Schemes for Anti-tuberculosis Therapy Induced Liver Injury in China. <b>2018</b> , 13, 53-63	7

486	Critical evaluation of causality assessment of herb-drug interactions in patients. <b>2018</b> , 84, 679-693	63
485	New Onset Autoimmune Hepatitis during Anti-Tumor Necrosis Factor-Alpha Treatment in Children. <b>2018</b> , 194, 128-135.e1	12
484	Heavy Consumption of Alcohol is Not Associated With Worse Outcomes in Patients With Idiosyncratic Drug-induced Liver Injury Compared to Non-Drinkers. <b>2018</b> , 16, 722-729.e2	22
483	Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry. <b>2018</b> , 16, 1495-1502	55
482	Drug-induced liver injury is frequently associated with severe cutaneous adverse drug reactions: experience from two Australian tertiary hospitals. <b>2018</b> , 48, 549-555	11
481	Clinical characteristics and outcomes of traditional Chinese medicine-induced liver injury: a systematic review. <b>2018</b> , 12, 425-434	28
480	Cefazolin Induced Liver Injury and Hypoprothrombinemia. <b>2018</b> , 8, 213-214	3
479	Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study. <b>2018</b> , 16, 46	29
478	Alcoholic steatohepatitis (ASH) and alcoholic hepatitis (AH): cascade of events, clinical aspects, and pharmacotherapy options. <b>2018</b> , 19, 779-793	19
477	Guidelines for the Diagnosis and Management of Herb-Induced Liver Injury. <b>2018</b> , 24, 696-706	34
476	Causality Assessment Methods in Drug-Induced Liver Injury. <b>2018</b> , 555-594	13
475	Acute Liver Failure from Tumor Necrosis Factor- $\alpha$ Antagonists: Report of Four Cases and Literature Review. <b>2018</b> , 63, 1654-1666	16
474	Perspectives on the Regulatory and Clinical Science of Drug-Induced Liver Injury (DILI). <b>2018</b> , 367-393	3
473	Hy $\bar{B}$ Law and eDISH for Clinical Studies. <b>2018</b> , 411-429	
472	Host Risk Modifiers in Idiosyncratic Drug-Induced Liver Injury (DILI) and Its Interplay with Drug Properties. <b>2018</b> , 477-496	1
471	Human Leukocyte Antigen (HLA) and Other Genetic Risk Factors in Drug-Induced Liver Injury (DILI). <b>2018</b> , 497-509	
470	Ibrutinib-induced acute liver failure. <b>2018</b> , 59, 512-514	7
469	Clinical Features of Regorafenib-induced Liver Injury in Japanese Patients From Postmarketing Experience. <b>2018</b> , 17, e49-e58	11

468	Drug-induced bile duct injury. <b>2018</b> , 1864, 1498-1506	37
467	Agreement Among Different Scales for Causality Assessment in Drug-Induced Liver Injury. <b>2018</b> , 38, 211-218	12
466	Drug-induced acute liver failure in children and adults: Results of a single-centre study of 128 patients. <b>2018</b> , 38, 1322-1329	31
465	Sex-dependent differences in inflammatory responses during liver regeneration in a murine model of acute liver injury. <b>2018</b> , 132, 255-272	13
464	Rivaroxaban-induced hepatotoxicity: review of the literature and report of new cases. <b>2018</b> , 30, 226-232	20
463	Acute liver failure induced by idiosyncratic reaction to drugs: Challenges in diagnosis and therapy. <b>2018</b> , 38, 6-14	38
462	Drug-induced autoimmune hepatitis associated with turmeric dietary supplement use. <b>2018</b> , 2018,	17
461	Methylprednisolone-induced acute liver injury in a patient treated for multiple sclerosis relapse. <b>2018</b> , 2018,	5
460	N,N-Dimethylacetamid [MAK Value Documentation in German language, 2018]. <b>2018</b> , 3, 1321-1343	
459	Optimizing diagnostic approach to drug-induced liver injury. <b>2018</b> , 12, 180-189	2
458	Hepatotoxicity by Drugs. <b>2018</b> ,	2
457	Idiosyncratic Drug-Induced Liver Injury Due to Ciprofloxacin: A Report of Two Cases and Review of the Literature. <b>2018</b> , 19, 1152-1161	19
456	Drug-Induced Liver Injury Associated with the Use of Everolimus in a Liver Transplant Patient. <b>2018</b> , 2018, 7410508	5
455	Kombiglyze (metformin and saxagliptin)-induced hepatotoxicity in a patient with non-alcoholic fatty liver disease. <b>2018</b> , 2, 242-245	4
454	Top-ranking drugs out of 3312 drug-induced liver injury cases evaluated by the Roussel Uclaf Causality Assessment Method. <b>2018</b> , 14, 1169-1187	24
453	Radiobiological doses, tumor, and treatment features influence on outcomes after episcleral brachytherapy. A 20-year retrospective analysis from a single-institution: part II. <b>2018</b> , 10, 347-359	12
452	The hepatotoxic potential of protein kinase inhibitors predicted with Random Forest and Artificial Neural Networks. <b>2018</b> , 299, 145-148	9
451	Traditional Chinese Medicine and Herb-induced Liver Injury: Comparison with Drug-induced Liver Injury. <b>2018</b> , 6, 57-68	46

450	Clerodane furanoditerpenoids as the probable cause of toxic hepatitis induced by <i>Tinospora crispa</i> . <b>2018</b> , 8, 13520	5
449	Acetaminophen administration and the risk of acute kidney injury: a self-controlled case series study. <b>2018</b> , 10, 265-276	15
448	rs1800796 of the IL6 gene is associated with increased risk for anti-tuberculosis drug-induced hepatotoxicity in Chinese Han children. <b>2018</b> , 111, 71-77	5
447	Development and Validation of a Test to Identify Drugs That Cause Idiosyncratic Drug-Induced Liver Injury. <b>2018</b> , 16, 1488-1494.e5	34
446	Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials. <b>2018</b> , 2018, 5253623	44
445	Drug-induced liver injury: a safety review. <b>2018</b> , 17, 795-804	21
444	Viral Hepatitis. <b>2018</b> , 372-415	3
443	Bicalutamide-Associated Acute Liver Injury and Migratory Arthralgia: A Rare but Clinically Important Adverse Effect. <b>2018</b> , 12, 266-270	2
442	Novel Approaches to Causality Adjudication in Drug-Induced Liver Disease. <b>2018</b> , 17, 276-282	7
441	Co-infection with hepatitis B virus among tuberculosis patients is associated with poor outcomes during anti-tuberculosis treatment. <b>2018</b> , 18, 295	26
440	Drugs and Toxins. <b>2018</b> , 673-779	9
439	Identification of Specific MicroRNA Biomarkers in Early Stages of Hepatocellular Injury, Cholestasis, and Steatosis in Rats. <b>2018</b> , 166, 228-239	21
438	Acute Hepatitis due to <i>Garcinia Cambogia</i> Extract, an Herbal Weight Loss Supplement. <b>2018</b> , 2018, 9606171	11
437	Liver Injury Due to Drugs and Herbal Agents. <b>2018</b> , 327-370	0
436	Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan. <b>2018</b> , 111, 121-126	20
435	Carbamazepine adverse drug reactions. <b>2018</b> , 11, 705-718	34
434	Botanicals and Hepatotoxicity. <b>2018</b> , 104, 458-469	14
433	HUME: large-scale detection of causal genetic factors of adverse drug reactions. <b>2018</b> , 34, 4274-4283	5

432	Single-Dose Rivaroxaban-Induced Acute Liver Injury. <b>2019</b> , 26, e538-e540	1
431	Clinicopathological features of He Shou Wu-induced liver injury: This ancient anti-aging therapy is not liver-friendly. <b>2019</b> , 39, 389-400	13
430	Carvedilol-Induced Liver Injury, a Rare Cause of Mixed Hepatitis: A Clinical Case. <b>2019</b> , 26, 196-201	4
429	The diagnosis and management of idiosyncratic drug-induced liver injury. <b>2019</b> , 39, 31-41	26
428	Idiosyncratic DILI: Analysis of 46,266 Cases Assessed for Causality by RUCAM and Published From 2014 to Early 2019. <b>2019</b> , 10, 730	32
427	Need for Causality Assessment Tool for Drug-induced Acute Kidney Injury. <b>2019</b> , 41, 1894-1897	0
426	A prospective study on associations between superoxide dismutase gene polymorphisms and antituberculosis drug-induced liver injury in a Chinese Han population. <b>2019</b> , 21, e3121	3
425	Regional and Racial Differences in Drug-Induced Liver Injury. <b>2019</b> , 18, 280-286	
424	Suspected adverse reactions associated with herbal products used for weight loss: spontaneous reports from the Italian Phytovigilance System. <b>2019</b> , 75, 1599-1615	2
423	Drug-Induced Liver Injury - Types and Phenotypes. <b>2019</b> , 381, 264-273	171
422	Association between genetic polymorphisms of SLCO1B1 and susceptibility to methimazole-induced liver injury. <b>2019</b> , 125, 508-517	6
421	Apixaban-induced fatal liver injury with a cholestatic pattern: A case report and brief review of the Literature. <b>2019</b> , 70, e17-e18	0
420	Assessing Causation from Case Reports. <b>2019</b> , 723-745	1
419	A rare case of norethisterone-related drug-induced liver injury. <b>2019</b> , 80, 476-477	1
418	Drug-induced liver injury. <b>2019</b> , 5, 58	148
417	The challenges of handling deferasirox in sickle cell disease patients older than 40 years. <b>2019</b> , 24, 596-600	3
416	Chemotherapy-induced liver injury in children. <b>2019</b> , 91, 256-263	1
415	Acute Liver Failure in a Patient Treated With Metamizole. <b>2019</b> , 10, 996	8

414	Toxicology and Drug Interactions of Nutraceuticals. <b>2019</b> , 711-727	1
413	Immune-mediated Drug-induced Liver Injury Caused by Laninamivir Octanoate Hydrate. <b>2019</b> , 58, 2501-2505	2
412	Association of HLA-C*03:02 with methimazole-induced liver injury in Graves' disease patients. <b>2019</b> , 117, 109095	10
411	A Novel MicroRNA Signature for Cholestatic Drugs in Human Hepatocytes and Its Translation into Novel Circulating Biomarkers for Drug-Induced Liver Injury Patients. <b>2020</b> , 173, 229-243	3
410	Turmeric Induced Liver Injury: A Report of Two Cases. <b>2019</b> , 2019, 6741213	16
409	RUCAM-based assessment of liver injury by xiang-tian-guo ( <i>Swietenia macrophylla</i> ) seeds, a plant used for treatment of hypertension and diabetes. <b>2019</b> , 18, 406-407	7
408	Inflammatory Phenotype of Intrahepatic Sulfatide-Reactive Type II NKT Cells in Humans With Autoimmune Hepatitis. <b>2019</b> , 10, 1065	9
407	"Hepatic toxicity by methotrexate with weekly single doses associated with folic acid in rheumatoid and psoriatic arthritis. What is its real frequency?". <b>2019</b> , 18, 765-769	9
406	Idiosyncratic drug-induced liver injury in patients: Detection, severity assessment, and regulatory implications. <b>2019</b> , 85, 165-193	8
405	Editorial: post-operative elevation of liver enzymes and modern volatile anaesthetics-guilty as charged?. <b>2019</b> , 49, 1245-1246	0
404	Chinese Herbal Medicine Hepatotoxicity: The Evaluation and Recognition Based on Large-scale Evidence Database. <b>2019</b> , 20, 138-146	12
403	Incidence and Etiology of Drug-Induced Liver Injury in Mainland China. <b>2019</b> , 156, 2230-2241.e11	185
402	Metabolomics and Cytokine Analysis for Identification of Severe Drug-Induced Liver Injury. <b>2019</b> , 18, 2514-2524	21
401	Clonazepam-induced liver dysfunction, severe hyperlipidaemia, and hyperglycaemic crisis: A case report. <b>2019</b> , 7, 2050313X19842976	3
400	Epidemiology of drug-induced liver injury in a University Hospital from Colombia: Updated RUCAM being used for prospective causality assessment. <b>2019</b> , 18, 501-507	10
399	Assessment of Serious Acute and Chronic Idiosyncratic Drug-Induced Liver Injury in Clinical Practice. <b>2019</b> , 39, 381-394	14
398	Liver injury after methylprednisolone pulses: A disputable cause of hepatotoxicity. A case series and literature review. <b>2019</b> , 7, 825-837	11
397	variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis. <b>2019</b> , 23, 293-305	13

396	Risk of Acute Liver Injury in Agomelatine and Other Antidepressant Users in Four European Countries: A Cohort and Nested Case-Control Study Using Automated Health Data Sources. <b>2019</b> , 33, 383-395	13
395	EASL Clinical Practice Guidelines: Drug-induced liver injury. <b>2019</b> , 70, 1222-1261	327
394	Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement. <b>2019</b> , 75, 1135-1141	10
393	[Immune-mediated cholangiopathies : Diagnostic and therapeutic challenges]. <b>2019</b> , 59, 348-356	
392	Patient Assessment in Clinical Pharmacy. <b>2019</b> ,	2
391	A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. <b>2019</b> , 156, 1707-1716.e2	59
390	Liver Function Assessment. <b>2019</b> , 309-319	0
389	A prospective study of the incidence of drug-induced liver injury by the modern volatile anaesthetics sevoflurane and desflurane. <b>2019</b> , 49, 940-951	4
388	Drug-Induced Liver Disease: Mechanism and Diagnosis. <b>2019</b> , 715-728	1
387	Hepatopatías tóxicas medicamentosas y no medicamentosas: generalidades. <b>2019</b> , 23, 1-9	
386	[Chemotherapy-induced liver injury in children]. <b>2019</b> , 91, 256-263	2
385	Pharmacovigilance - The next chapter. <b>2019</b> , 74, 557-567	82
384	Clinical Features of Liver Injury Induced by Immune Checkpoint Inhibitors in Japanese Patients. <b>2019</b> , 2019, 6391712	24
383	Stimulating More Than Just the Granulocytes: Drug-Induced Liver Injury From Filgrastim. <b>2019</b> , 6, e00098	0
382	N,N-Dimethylacetamide [MAK Value Documentation, 2018]. <b>2019</b> , 4, 2003-2026	
381	An electronic medical records-based approach to identify idiosyncratic drug-induced liver injury in children. <b>2019</b> , 9, 18090	2
380	Drug-induced liver injury due to mesterolone: A case report. <b>2019</b> , 42, 629-630	
379	Antimicrobials and Antiepileptics Are the Leading Causes of Idiosyncratic Drug-induced Liver Injury in American Children. <b>2019</b> , 69, 152-159	9

378	Biomarkers of Drug-Induced Liver Toxicity. <b>2019</b> , 41, 227-234	7
377	Tools for causality assessment in drug-induced liver disease. <b>2019</b> , 35, 183-190	16
376	Assessment of cholestasis in drug-induced liver injury by different methods. <b>2019</b> , 98, e14399	3
375	Serum metabolome and targeted bile acid profiling reveals potential novel biomarkers for drug-induced liver injury. <b>2019</b> , 98, e16717	18
374	Herb-Induced Liver Injury With Cholestasis and Renal Injury Secondary to Short-Term Use of Kratom ( <i>Mitragyna speciosa</i> ). <b>2019</b> , 26, e546-e547	15
373	Liver injury induced by levothyroxine tablets in a patient with hypothyroidism. <b>2019</b> , 132, 2015-2016	1
372	Idiosyncratic Liver Injury Due to Levocetirizine. <b>2019</b> , 6, e00191	
371	Analysis of 307 cases with drug-induced liver injury between 2010 and 2018 in Japan. <b>2019</b> , 49, 105-110	27
370	Guidance for the clinical evaluation of traditional Chinese medicine-induced liver injury Issued by China Food and Drug Administration. <b>2019</b> , 9, 648-658	12
369	Cholestatic Drug-Induced Liver Injury Caused by Mifepristone. <b>2019</b> , 69, 2704-2706	7
368	Current status of pharmacovigilance regulatory structures, processes, and outcomes in the Asia-Pacific region: Survey results from 15 countries. <b>2019</b> , 28, 362-369	2
367	Acute severe hepatitis with alemtuzumab and rechallenge after a year. <b>2019</b> , 60, 158-160	4
366	Previous Drug Exposure in Patients Hospitalised for Acute Liver Injury: A Case-Population Study in the French National Healthcare Data System. <b>2019</b> , 42, 559-572	9
365	Prediction of clinically relevant drug-induced liver injury from structure using machine learning. <b>2019</b> , 39, 412-419	17
364	Drug-induced liver injury with skin reactions: Drugs and host risk factors, clinical phenotypes and prognosis. <b>2019</b> , 39, 802-811	14
363	Fluoxetine-induced Stevens-Johnson syndrome and liver injury. <b>2019</b> , 44, 115-118	6
362	Drug-induced liver injury secondary to anabolic steroid use. <b>2020</b> , 85, 92-94	1
361	Automated Machine Learning Diagnostic Support System as a Computational Biomarker for Detecting Drug-Induced Liver Injury Patterns in Whole Slide Liver Pathology Images. <b>2020</b> , 18, 1-10	6

360	Fructus Psoraleae-Induced Severe Liver Injury and Treatment With Two Artificial Liver Support Systems: A Case Series Study. <b>2020</b> , 24, 324-332	2
359	Epidemiology and outcomes of marked elevations of alanine aminotransferase >1000 IU/L in an Australian cohort. <b>2020</b> , 4, 106-112	0
358	Hepatotoxicity; Drug-Induced Liver Injury. <b>2020</b> , 183-203	
357	Drug-induced liver injury secondary to anabolic steroid use. <b>2020</b> , 85, 92-94	1
356	Definition of the Chemical and Immunological Signals Involved in Drug-Induced Liver Injury. <b>2020</b> , 33, 61-76	6
355	Drug Hepatotoxicity: Causality Assessment. <b>2020</b> , 24, 25-35	5
354	Diagnostic and prognostic assessment of suspected drug-induced liver injury in clinical practice. <b>2020</b> , 40, 6-17	16
353	Utility of a Computerized ICD-10 Algorithm to Identify Idiosyncratic Drug-Induced Liver Injury Cases in the Electronic Medical Record. <b>2020</b> , 43, 371-377	4
352	Kratom ( <i>Mitragyna Speciosa</i> ) Liver Injury: A Comprehensive Review. <b>2020</b> , 80, 263-283	20
351	Diagnostic Biomarkers in Liver Injury by Drugs, Herbs, and Alcohol: Tricky Dilemma after EMA Correctly and Officially Retracted Letter of Support. <b>2019</b> , 21,	14
350	Genetic Polymorphisms in Antioxidant Enzymes Modulate the Susceptibility of Idiosyncratic Antituberculous Drug-Induced Liver Injury and Treatment Outcomes in Patients with Tuberculosis. <b>2020</b> , 40, 4-16	3
349	Epistane, an anabolic steroid used for recreational purposes, causes cholestasis with elevated levels of cholic acid conjugates, by upregulating bile acid synthesis (CYP8B1) and cross-talking with nuclear receptors in human hepatocytes. <b>2020</b> , 94, 589-607	10
348	Transcriptomic analysis reveals the mechanism of sulfasalazine-induced liver injury in mice. <b>2020</b> , 321, 12-20	10
347	Drug-Induced Liver Injury in the Setting of Chronic Liver Disease. <b>2020</b> , 24, 89-106	6
346	Idiosyncratic Drug-Induced Liver Injury Secondary to Trimethoprim-Sulfamethoxazole. <b>2020</b> , 27, e664-e667	1
345	Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993-Mid 2020: A Comprehensive Analysis. <b>2020</b> , 7,	25
344	Avoidability of drug-induced liver injury (DILI) in an elderly hospital cohort with cases assessed for causality by the updated RUCAM score. <b>2020</b> , 20, 346	5
343	Apetamin Hepatotoxicity: Potential Consequences of Purchasing a Body Enhancement Drug Off the Internet. <b>2020</b> , 7, e00398	0

342	AN OVERVIEW OF VARIOUS SCALES USED IN CAUSALITY ASSESSMENT OF ADVERSE DRUG REACTIONS. <b>2020</b> , 1-5	
341	Appropriate chemopreventive strategy for anti-tubercular therapy related liver injury is unsettled: Results from a systematic review and network meta-analysis. <b>2020</b> , 13, 1253-1262	2
340	Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. <b>2020</b> , 2, 100170	23
339	Comparison of diagnostic accuracy of 3 diagnostic criteria combined with refined pathological scoring system for drug-induced liver injury. <b>2020</b> , 99, e22259	2
338	Potential Hepatotoxins Found in Herbal Medicinal Products: A Systematic Review. <b>2020</b> , 21,	16
337	CLIF-C Organ Failure Score and Liver Volume Predict Prognosis in Steroid-Treated Severe Acute Autoimmune Hepatitis. <b>2020</b> , 4, 1019-1033	1
336	An Evaluation of Postmarketing Reports of Serious Idiosyncratic Liver Injury Associated with Ulipristal Acetate for the Treatment of Uterine Fibroids. <b>2020</b> , 43, 1267-1276	8
335	A case of teriflunomide-induced hepatic injury: assessing causality using available rules. <b>2020</b> , 4, 62-66	1
334	Evidence of drug-induced hepatotoxicity in the Maghrebian population. <b>2020</b> , 1-5	5
333	Metabolomics analysis of plasma reveals voriconazole-induced hepatotoxicity is associated with oxidative stress. <b>2020</b> , 403, 115157	2
332	Multicenter Analysis of Liver Injury Patterns and Mortality in COVID-19. <b>2020</b> , 7, 584342	10
331	Liver Injury Among Japanese Patients Treated Using Prophylactic Enoxaparin After Colorectal Surgery. <b>2021</b> , 66, 2805-2815	2
330	Exploratory Study of Autoantibody Profiling in Drug-Induced Liver Injury with an Autoimmune Phenotype. <b>2020</b> , 4, 1651-1663	6
329	Drug induced liver injury: an update. <b>2020</b> , 94, 3381-3407	40
328	Plasma Lipid Profiling of Three Types of Drug-Induced Liver Injury in Japanese Patients: A Preliminary Study. <b>2020</b> , 10,	2
327	First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19. <b>2020</b> , 40, 1901-1905	51
326	The Origins of the Modern-Day Study of Drug Hepatotoxicity: Focus on Hyman J. Zimmerman. <b>2020</b> , 15, S25-S36	0
325	Knowledge Mapping of Drug-Induced Liver Injury: A Scientometric Investigation (2010-2019). <b>2020</b> , 11, 842	26

324	Translating new knowledge on drug-induced liver injury into clinical practice. <b>2020</b> , 11, 303-310	2
323	Liver injury caused by oral anticoagulants: A population-based retrospective cohort study. <b>2020</b> , 40, 1895-1900	9
322	Acute Liver Failure Caused by Use of Fat Burner: A Case Report. <b>2020</b> , 52, 1409-1412	3
321	Autoimmune Hepatitis Associated With Turmeric Consumption. <b>2020</b> , 7, e00320	6
320	Amplification-free profiling of microRNA-122 biomarker in DILI patient serums, using the luminex MAGPIX system. <b>2020</b> , 219, 121265	3
319	Mechanistic insights into antiretroviral drug-induced liver injury. <b>2020</b> , 8, e00598	5
318	Causality Assessment Guidelines for Adverse Events Following Immunization with a Focus on Guillain-Barré Syndrome. <b>2020</b> , 8,	2
317	Metamizole: An underrated agent causing severe idiosyncratic drug-induced liver injury. <b>2020</b> , 86, 1406-1415	11
316	Epigallocatechin-3-Gallate Toxicity in Children: A Potential and Current Toxicological Event in the Differential Diagnosis With Virus-Triggered Fulminant Hepatic Failure. <b>2019</b> , 10, 1563	7
315	United States Pharmacopeia (USP) comprehensive review of the hepatotoxicity of green tea extracts. <b>2020</b> , 7, 386-402	55
314	Molecular Biomarkers in Drug-Induced Liver Injury: Challenges and Future Perspectives. <b>2019</b> , 10, 1667	30
313	An unusually impressive atorvastatin-induced elevation of serum alkaline phosphatase. <b>2020</b> , 13,	3
312	A Dual-Emissive Phosphorescent Polymeric Probe for Exploring Drug-Induced Liver Injury via Imaging of Peroxynitrite Elevation In Vivo. <b>2020</b> , 12, 12383-12394	14
311	Clinical Characteristics of 162 Patients with Drug-Induced Liver and/or Kidney Injury. <b>2020</b> , 2020, 3930921	
310	Guidelines for the Management of Adult Acute and Acute-on-Chronic Liver Failure in the ICU: Cardiovascular, Endocrine, Hematologic, Pulmonary, and Renal Considerations. <b>2020</b> , 48, e173-e191	25
309	Ashwagandha-induced liver injury: A case series from Iceland and the US Drug-Induced Liver Injury Network. <b>2020</b> , 40, 825-829	22
308	Clinical characteristics, CT signs, and pathological findings of Pyrrolizidine alkaloids-induced sinusoidal obstructive syndrome: a retrospective study. <b>2020</b> , 20, 30	9
307	Drug-Induced Liver Injury in GI Practice. <b>2020</b> , 4, 631-645	20

306	Liver injury after methylprednisolone pulse therapy in multiple sclerosis is usually due to idiosyncratic drug-induced toxicity rather than autoimmune hepatitis. <b>2020</b> , 42, 102065	2
305	Immune-related hepatitis related to checkpoint inhibitors: Clinical and prognostic factors. <b>2020</b> , 40, 1906-1916	20
304	A retrospective case-controlled cohort study of inpatient drug induced liver injury: the RIDDLE study. <b>2020</b> , 5, 33	1
303	Drug induced liver injury is associated with high mortality-A study from a tertiary care hospital in Pakistan. <b>2020</b> , 15, e0231398	5
302	Profile of herbal and dietary supplements induced liver injury in Latin America: A systematic review of published reports. <b>2021</b> , 35, 6-19	6
301	Acute Hepatocellular Injury Associated With Azithromycin. <b>2021</b> , 34, 493-496	6
300	Unusual Presentation of Systemic Lupus Erythematosus in a Young Male: A Case Report. <b>2021</b> , 11, 264-269	0
299	Biomarkers of drug-induced liver injury: a mechanistic perspective through acetaminophen hepatotoxicity. <b>2021</b> , 15, 363-375	5
298	Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors. <b>2021</b> , 26, e863-e873	8
297	A case series analysis of serious exacerbations of viral hepatitis and non-viral hepatic injuries in tocilizumab-treated patients. <b>2021</b> , 41, 515-528	1
296	The Indian Network of Drug-Induced Liver Injury: Etiology, Clinical Features, Outcome and Prognostic Markers in 1288 Patients. <b>2021</b> , 11, 288-298	10
295	Safety of co-administration of herbal and conventional medicines on liver and kidney function in stroke patients: A single-center retrospective study. <b>2021</b> , 81, 153435	0
294	Profile of Hepatobiliary Dysfunction in Hematopoietic Stem Cell Transplant Recipients - An Indian Perspective. <b>2021</b> , 11, 14-20	1
293	Antimitochondrial Rather than Antinuclear Antibodies Correlate with Severe Drug-Induced Liver Injury. <b>2021</b> , 39, 275-282	5
292	Liraglutide-Induced Hepatotoxicity. <b>2021</b> , 9,	5
291	Drug-Induced Liver Injury in Older Adults. <b>2021</b> , 1391-1406	
290	Herb-Induced Liver Injury by Cimicifuga racemosa and Thuja occidentalis Herbal Medications for Fertility. <b>2021</b> , 2021, 8858310	
289	Colestasis inducida por anabólicos: reporte de caso y revisión de la literatura. <b>2021</b> , 273-281	0

288	The Use of Daptomycin in the Treatment of Persistent Coagulase-Negative Staphylococcal Sepsis in Premature Infants: A Case Series. <b>2021</b> , 26, 92-98	1
287	The role of liver steatosis as measured with transient elastography and transaminases on hard clinical outcomes in patients with COVID-19. <b>2021</b> , 14, 17562848211016567	2
286	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A case with adverse reaction to three drugs alternately administered. <b>2021</b> , 4, 001-005	
285	Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines. <b>2021</b> , 15, 258-282	15
284	The association of transporter ABCC2 (MRP2) genetic variation and drug-induced hyperbilirubinemia. <b>2021</b> , 84, 129-135	2
283	Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trials. <b>2021</b> , 164, 105404	9
282	Liver Injury Associated with Metamizole Exposure: Features of an Underestimated Adverse Event. <b>2021</b> , 44, 669-680	3
281	Drug Induced Liver Injury in Geriatric Patients Detected by a Two-Hospital Prospective Pharmacovigilance Program: A Comprehensive Analysis Using the Roussel Uclaf Causality Assessment Method. <b>2020</b> , 11, 600255	3
280	Sustained hyperbilirubinemia following clarithromycin administration. <b>2021</b> , 2, e0057	
279	Drug-induced liver injury associated with acenocumarol exposure. <b>2021</b> , 37, 120-123	0
278	Outcomes and Predictors of Mortality in Patients With Drug-Induced Liver Injury at a Tertiary Hospital in South India: A Single-Centre Experience. <b>2021</b> , 11, 163-170	2
277	Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice. <b>2021</b> , 10,	11
276	Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials. <b>2021</b> , 44, 619-634	2
275	Detecting Adverse Drug Events Through the Chronological Relationship Between the Medication Period and the Presence of Adverse Reactions From Electronic Medical Record Systems: Observational Study. <b>2021</b> , 9, e28763	
274	Drug properties and host factors contribute to biochemical presentation of drug-induced liver injury: a prediction model from a machine learning approach. <b>2021</b> , 95, 1793-1803	2
273	Valproic Acid-Induced Liver Injury: A Case-Control Study from a Prospective Pharmacovigilance Program in a Tertiary Hospital. <b>2021</b> , 10,	0
272	Idiosyncratic Drug-Induced Liver Injury (DILI) and Herb-Induced Liver Injury (HILI): Diagnostic Algorithm Based on the Quantitative Roussel Uclaf Causality Assessment Method (RUCAM). <b>2021</b> , 11,	10
271	A Novel Computer-Assisted Drug-Induced Liver Injury Causality Assessment Tool (DILI-CAT).	1

- 270 The method to detect the adverse drug events through the chronological relationship between the medication period and the presence of adverse reactions from electronic medical record systems. (Preprint).
- 269 Idiosyncratic Drug Induced Liver Injury, Cytochrome P450, Metabolic Risk Factors and Lipophilicity: Highlights and Controversies. **2021**, 22, 9
- 268 Causality assessment between reported fatal cerebral haemorrhage and suspected drugs: developing a new algorithm based on the analysis of the Japanese Adverse Event Report (JADER) database and literature review. **2021**, 77, 1443-1452
- 267 Acute liver failure after changing oral anticoagulant from apixaban to rivaroxaban. **2021**, 14, 2
- 266 Liver Injury Associated With Drugs and Complementary and Alternative Medicines in India. **2021**,
- 265 Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues. **2021**, 9, 730 4
- 264 An Approach to Drug-Induced Liver Injury from the Geriatric Perspective. **2021**, 23, 6 1
- 263 ,, and genetic polymorphisms and their associations with susceptibility to antituberculosis drug-induced liver injury in Thai tuberculosis patients. **2021**, 7, e06852
- 262 Roles of SET7/9 and LSD1 in the Pathogenesis of Arsenic-induced Hepatocyte Apoptosis. **2021**, 9, 364-372 1
- 261 Insight into an acute hepatitis A outbreak in Indiana. **2021**, 28, 964-971 4
- 260 Methods for identifying culprit drugs in cutaneous drug eruptions: A scoping review.
- 259 Liver Injury Associated With Drugs and Complementary and Alternative Medicines in India. **2021**, 11, 281-283 1
- 258 ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. **2021**, 116, 878-898 31
- 257 Case report: Secondary sclerosing cholangitis induced by lapatinib and vinorelbine in a metastasis breast cancer patient. **2021**, 12, 1912-1916 1
- 256 Incidence and risk factors of anti-tuberculosis drug induced liver injury (DILI): Large cohort study involving 4652 Chinese adult tuberculosis patients. **2021**, 41, 1565-1575 3
- 255 Disulfiram hepatotoxicity: Report of three cases. **2021**, 158, 145-145 0
- 254 Incidence, characteristics and risk factors for drug-induced liver injury in hospitalized patients: A matched case-control study. **2021**, 87, 4304-4312 0
- 253 Clinical management of patients with drug-induced liver injury (DILI). **2021**, 9, 781-786 2

252	Liver injury associated with the use of selective androgen receptor modulators and post-cycle therapy: Two case reports and literature review. <b>2021</b> , 9, 4062-4071	5
251	Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy. <b>2021</b> , 16, e0253070	2
250	Sulfamethoxazole-trimethoprim-induced liver injury and genetic polymorphisms of NAT2 and CYP2C9 in Taiwan. <b>2021</b> , 31, 200-206	
249	Drug-induced liver injury in Australia, 2009-2020: the increasing proportion of non-paracetamol cases linked with herbal and dietary supplements. <b>2021</b> , 215, 261-268	3
248	Drug-induced liver injury at a tertiary care centre in Germany: Model for end-stage liver disease is the best predictor of outcome. <b>2021</b> , 41, 2383-2395	0
247	Drug-induced liver injury associated with severe cutaneous adverse drug reactions: A nationwide study in Taiwan. <b>2021</b> , 41, 2671-2680	2
246	The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review. <b>2021</b> , 35, 861-880	3
245	Clinical Course and Treatment Implications of Combination Immune Checkpoint Inhibitor-Mediated Hepatitis: A Multicentre Cohort.. <b>2022</b> , 5, 39-47	2
244	Metabolomic analysis to discriminate drug-induced liver injury (DILI) phenotypes. <b>2021</b> , 95, 3049-3062	2
243	Herb-induced liver injury (HILI) with 12,068 worldwide cases published with causality assessments by Roussel Uclaf Causality Assessment Method (RUCAM): an overview. <b>2021</b> , 6, 51	8
242	The Diagnosis of Drug-induced Liver Injury: Current Diagnostic Ability and Future Challenges of the Digestive Disease Week-Japan 2004 Scale 15 Years after Its Proposal. <b>2021</b> , 60, 2557-2568	1
241	Herbal and dietary supplement-induced liver injury in Taiwan: comparison with conventional drug-induced liver injury. <b>2021</b> , 15, 1456-1465	2
240	Exploring the efficacy and safety of polyene phosphatidylcholine for treatment of drug-induced liver injury using the Roussel Uclaf causality assessment method: a propensity score matching comparison. <b>2021</b> , 49, 3000605211039810	4
239	Immune checkpoint inhibitor-related hepatotoxicity: A review. <b>2021</b> , 27, 5376-5391	10
238	Causality imputation between herbal products and HILI: An algorithm evaluation in a systematic review. <b>2021</b> , 25, 100539	2
237	Association of human leukocyte antigen-B*13:01 with dapsone-induced liver injury. <b>2021</b> ,	1
236	A Multiple Logistic Regression Model Based on Gamma-Glutamyl Transferase as a Biomarker for Early Prediction of Drug-Induced Liver Injury in Vietnamese Patients. <b>2021</b> ,	
235	VALPROİK ASİT KULLANIMINA BAĞLI TROMBOSTOPENİVE FULMİNAN KARACER YETERSİZLİĞİ ÖLĞÜ SUNUMU. 483-486	

234	The LiverTox Paradox-Gaps between Promised Data and Reality Check. <b>2021</b> , 11,	5
233	Metabolic Toxicification of 1,2-Unsaturated Pyrrolizidine Alkaloids Causes Human Hepatic Sinusoidal Obstruction Syndrome: The Update. <b>2021</b> , 22,	7
232	Assessing Causality of Case Reports of Suspected Adverse Events. 581-600	1
231	Drug Induced Liver Disease: Mechanisms and Diagnosis. <b>2010</b> , 771-786	0
230	Drug-Induced Liver Injury: Clinical and Diagnostic Aspects. 81-106	1
229	Drug-Induced Liver Injury After Liver Transplantation. <b>2020</b> , 26, 1167-1176	3
228	Adverse reactions and their mechanisms from nimesulide. <b>2005</b> , 315-415	5
227	Drug-Induced Liver Injury in Older Adults. <b>2020</b> , 1-16	1
226	Drug-Induced Liver Injury. <b>2012</b> , 2113-2117	1
225	Roles of Hepatic Drug Transporters in Drug Disposition and Liver Toxicity. <b>2019</b> , 1141, 293-340	13
224	Liver Disease Caused by Drugs. <b>2010</b> , 1413-1446.e8	2
223	Drug-induced liver injury due to mesterolone: A case report. <b>2019</b> , 42, 629-630	2
222	[Probable dissociated cholestasis associated with topiramate]. <b>2019</b> , 54, 303-305	1
221	[Fatal liver disease due to amoxicillin-clavulanic acid in nonagenarian patient]. <b>2019</b> , 54, 357-359	0
220	[Does methylphenidate cause liver damage? An analysis of ad hoc reports to the "Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)"]. <b>2018</b> , 46, 342-348	1
219	Euforia-induced acute hepatitis in a patient with scleroderma. <b>2012</b> , 2012,	9
218	Acute liver injury associated with a newer formulation of the herbal weight loss supplement Hydroxycut. <b>2015</b> , 2015,	9
217	Flupirtine drug-induced liver injury in a patient developing acute liver failure. <b>2018</b> , 2018,	2

216	Acute liver injury associated with the use of herbal preparations containing glucosamine: three case studies. <b>2009</b> , 2009,	11
215	Incidence and associated risk factors of antituberculosis drug-induced hepatotoxicity among hospitalised patients in Wuhan, China. <b>2020</b> ,	1
214	Case Report: Levetiracetam causing acute liver failure complicating post-operative management in a neurosurgical patient. <b>2019</b> , 8, 187	3
213	Drug-induced liver injury. <b>2020</b> , 37, 2-12	11
212	Acute hepatitis after amiodarone infusion. <b>2015</b> , 3, 900-3	6
211	Liver involvement in the drug reaction, eosinophilia, and systemic symptoms syndrome. <b>2019</b> , 7, 705-716	12
210	Plasma microRNA profiles in rat models of hepatocellular injury, cholestasis, and steatosis. <b>2012</b> , 7, e30250	74
209	Impact of glutathione S-transferase M1 and T1 on anti-tuberculosis drug-induced hepatotoxicity in Chinese pediatric patients. <b>2014</b> , 9, e115410	13
208	Drug- and Herb-Induced Liver Injury in Clinical and Translational Hepatology: Causality Assessment Methods, Quo Vadis?. <b>2013</b> , 1, 59-74	13
207	Herb-induced Liver Injury in Asia and Current Role of RUCAM for Causality Assessment in 11,160 Published Cases. <b>2020</b> , 8, 200-214	15
206	Apixaban-induced liver injury. <b>2019</b> , 111, 161-163	2
205	Acute hepatocellular drug-induced liver injury probably caused by doxazosin. <b>2021</b> , 113, 301-302	2
204	Retrospective study of idiosyncratic drug-induced liver injury from infliximab in an inflammatory bowel disease cohort: the IDLE study. <b>2020</b> , 33, 162-169	7
203	Comparison of Three Pharmacovigilance Algorithms in the ICU Setting. <b>2012</b> , 35, 645	3
202	Suspected herbal hepatotoxicity: requirements for appropriate causality assessment by the US Pharmacopeia. <b>2012</b> , 35, 1091-7	14
201	Drug-Induced Liver Injuries (Clinical Guidelines for Physicians). <b>2019</b> , 29, 101-131	22
200	Recurrent albendazole-induced acute hepatitis. <b>2018</b> , 33, 473	1
199	Parenteral amiodarone-induced hepatotoxicity: when being earnest is an added value. <b>2019</b> , 178,	1

198	Cholestatic hepatic injury related to administration of sodium risedronate hydrate. A case report with distinctive histological findings. <b>2006</b> , 47, 10-15	1
197	Management of imatinib mesilate (IM)-related hepatic injury by adjusting the dose of the drug in a patient with chronic myelogenous leukemia (CML): A case report. <b>2007</b> , 48, 505-510	1
196	ADRIC: Adverse Drug Reactions In Children [a] programme of research using mixed methods. <b>2014</b> , 2, 1-184	8
195	Drug-induced liver injury caused by iodine-131. <b>2016</b> , 22, 272-5	5
194	Ombitasvir/paritaprevir/ritonavir+dasabuvir and ribavirin associated drug-induced liver injury and syndrome of inappropriate secretion of anti-diuretic hormone: A case report. <b>2019</b> , 25, 326-330	3
193	Alfuzosin-induced acute liver injury. <b>2007</b> , 13, 414-8	9
192	[Two cases of toxic hepatitis caused by arrowroot juice]. <b>2009</b> , 15, 504-9	17
191	Celecoxib-induced cholestatic liver failure requiring orthotopic liver transplantation. <b>2009</b> , 15, 3937-9	23
190	Evaluation of prognostic markers in severe drug-induced liver disease. <b>2007</b> , 13, 628-32	37
189	Drug-induced liver injury in hospitalized patients with notably elevated alanine aminotransferase. <b>2012</b> , 18, 5972-8	24
188	Anxiety and depression propensities in patients with acute toxic liver injury. <b>2013</b> , 19, 9069-76	15
187	Clinical characteristics of drug-induced liver injury and primary biliary cirrhosis. <b>2016</b> , 22, 7579-86	7
186	Role of non-steroidal anti-inflammatory drugs on intestinal permeability and nonalcoholic fatty liver disease. <b>2017</b> , 23, 3954-3963	44
185	Single-nucleotide polymorphisms of and -induced liver injury in the Han Chinese population. <b>2020</b> , 26, 1329-1339	8
184	Acute Liver Failure after Initiation of Rivaroxaban: A Case Report and Review of the Literature. <b>2015</b> , 7, 407-10	10
183	Losartan-induced Ischemic Hepatocellular Hepatotoxicity: A Case Report and Literature Review. <b>2014</b> , 3, 272-4	7
182	Topiramate-induced acute liver injury: A rare adverse effect. <b>2017</b> , 49, 254-256	1
181	Evaluation of Drug-Induced Liver Injury Developed During Hospitalization Using Electronic Health Record (EHR)-Based Algorithm. <b>2020</b> , 12, 430-442	7

180	Acute hepatitis associated with the use of natural product camu-camu. <b>2013</b> , 03, 214-216	2
179	Escitalopram-induced liver injury: A case report and review of literature. <b>2019</b> , 11, 719-724	4
178	Drug and herbal/dietary supplements-induced liver injury: A tertiary care center experience. <b>2020</b> , 12, 207-219	3
177	Khat (Catha Edulis) as a possible cause of autoimmune hepatitis. <b>2014</b> , 6, 150-4	18
176	Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease. <b>2014</b> , 6, 160-8	69
175	Drug-induced liver injury: Do we know everything?. <b>2017</b> , 9, 491-502	47
174	Causes, Features, and Outcomes of Drug-Induced Liver Injury in 69 Children from China. <b>2015</b> , 9, 525-33	27
173	Drug-Induced Liver Injury: Pattern Recognition and Future Directions. <b>2016</b> , 10, 27-36	34
172	Atorvastatin-induced acute elevation of hepatic enzymes and the absence of cross-toxicity of pravastatin. <b>2010</b> , 48, 798-802	20
171	Hepatology highlights. <b>2015</b> , 14, 772-773	3
170	Metoprolol-induced Severe Liver Injury and Successful Management with Therapeutic Plasma Exchange. <b>2017</b> , 9, e1209	2
169	Autoimmune-like Drug-induced Liver Injury Caused by Atorvastatin and Demonstration of the Safety Profile of Pravastatin: A Case Report and Literature Review. <b>2020</b> , 12, e7299	3
168	S2637 Kombucha-Induced Liver Injury. <b>2021</b> , 116, S1107-S1107	
167	The Unmet Needs of Hepatitis E Virus Diagnosis in Suspected Drug-Induced Liver Injury in Limited Resource Setting. <b>2021</b> , 12, 737486	0
166	Role of Ursodeoxycholic Acid in Treating and Preventing Idiosyncratic Drug-Induced Liver Injury. A Systematic Review. <b>2021</b> , 12, 744488	4
165	Treatment of Digital Ulcers and Reflux Oesophagitis in a Patient with Systemic Sclerosis: Increased Risk of Hepatotoxicity due to a Potential Drug-drug Interaction Between Bosentan and Vonoprazan. <b>2021</b> , 101, adv00600	2
164	Sports nutrition supplements and adverse events - a meta-epidemiological study of case reports specifically addressing causality assessment. <b>2021</b> , 1	1
163	Drug Induced Liver Injury. <b>2022</b> , 411-442	

- 162 Clinical characteristics and outcomes of drug-induced liver injury in Taiwan with an emphasis on the impact of chronic hepatitis B infection. **2021**, 0
- 161 Probable hepatotoxicity from two second-generation integrase strand transfer inhibitors. **2021**, 35, 2232-2233 0
- 160 Assessment of Liver Function in Clinical Practice. **2011**, 47-76 3
- 159 Drug-Induced Liver Injury in Children: A Structured Approach to Diagnosis and Management. **2014**, 371-388
- 158 Arzneimittelinduzierte Leberschäden. **2014**, 1-9
- 157 A Case of Primaquine-Induced Acute Liver Failure. **2014**, 86, 54 1
- 156 Cyproheptadine for central hypertension?. **2014**, 12
- 155 Drug-Induced Cholestasis. **2014**, 13-31 1
- 154 Medikamenten induzierte Schäden im Gastrointestinaltrakt. **2015**, 637-654
- 153 Drug-Induced Liver Disease. 1958-1972
- 152 Arzneimittelinduzierte Leberschäden. **2016**, 119-127
- 151 Mononuclear syndrome with acute hepatitis diagnosed as Mycoplasma pneumoniae infection without lung involvement. **2016**, 36, 81-4
- 150 Arzneimittelinduzierte Leberschäden. **2016**, 119-127
- 149 Canalicular cholestasis induced by anabolic steroids. **2017**, 109, 735-736 1
- 148 Essential phospholipids use in the treatment of drug-induced liver injury in pregnant women. **2017**, 66, 14-23 1
- 147 Hépatites toxiques et médicamenteuses. **2018**, 199-203
- 146 Cefixime-induced hepatotoxicity and acute renal failure: a case report. 55-58
- 145 Drug and herbal hepatotoxicity: an overview of clinical classifications. **2018**, 64, 384-393 2

- 144 Concurrent Use of Nefopam vs. Ketorolac with Opioid Analgesic for Post-operative Pain Management. **2018**, 28, 279-284
- 143 Rituximab induced transaminitis in pemphigus foliaceus. 1, 45-47
- 142 A Rare Presentation of Drug-induced Liver Injury with Fluticasone and Vilanterol Inhaler Use. **2019**, 11, e4933
- 141 Sodium Valproate versus Continuous Infusion of Haloperidol in Management of Agitated Critically Ill Patients. **2019**, 7, 2440-2443
- 140 No existen fármacos inocentes: daño hepatocelular inducido por desloratadina. **2019**, 4, 111-114
- 139 Drugs-induced liver injury associated with non-steroidal anti-inflammatory drugs: a case report and clinical insights. **2019**, 47, 579-591 1
- 138 Immune-Mediated Drug-Induced Liver Injury. **2020**, 491-504
- 137 Drug and herbal/dietary supplements-induced liver injury: A tertiary care center experience. **2020**, 12, 197-209
- 136 Drug Induced Liver Injury (DILI) and Non Alcoholic Fatty Liver Disease (NAFLD). **2020**, 2,
- 135 Hepatotoxicity: A Baseless Accusation. Cases Assessed for Causality Using RUCAM Method. **2021**, 12, 780330 2
- 134 Chinese Herbal Medicine-Induced Rapid Liver Cirrhosis: A Case Report. **2021**, 21,
- 133 Vedolizumab-Induced Liver Injury.. **2021**, 28, 410-415
- 132 Drug-Induced Liver Injury from Anti-Tuberculosis Treatment: A Retrospective Cohort Study. **2020**, 26, e920350 4
- 131 Acetaminophen syn. Paracetamol: Acute Liver Injury and Acute on Chronic Liver Failure with Case Analysis and Causality Assessment Using RUCAM. **2020**, 233-258 0
- 130 Drug-Induced Liver Injury: Clinical and Etiologic Features at a Large Tertiary Teaching Hospital in China. **2020**, 26, e919435 1
- 129 Hepatotoxicity: Mechanisms of Liver Injury. **2020**, 75-84 1
- 128 Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. **2021**, 158, 112664 3
- 127 Hepatotoxicity with cholestatic pattern secondary to enoxaparin treatment. **2021**,

126	Falla hepática subaguda secundaria a hepatotoxicidad severa por medicamentos: reporte de caso. <b>2020</b> , 165-175	
125	Clinical features and prognosis of drug-induced liver injury under hypoxia conditions. <b>2020</b> , 28, 587-593	
124	Hepatic Disease. <b>2004</b> , 463-490	
123	Drug-induced liver injury in cancer patients. <b>2020</b> , 15, 80-94	
122	Republished: An unusually impressive atorvastatin-induced elevation of serum alkaline phosphatase. <b>2021</b> , 59, 43-47	
121	Vedolizumab-induced cholestatic liver injury. <b>2020</b> , 45, 64-64	0
120	Drug-induced Liver Injury. <b>2010</b> , 6, 73-80	53
119	Herbal and dietary supplement-induced liver injury. <b>2011</b> , 7, 695-6	6
118	Antituberculosis Drug-Induced Hepatotoxicity in Iranian Tuberculosis Patients: Role of Isoniazid Metabolic Polymorphism. <b>2011</b> , 10, 633-9	11
117	Evaluation considerations for EHR-based phenotyping algorithms: A case study for drug-induced liver injury. <b>2013</b> , 2013, 130-4	7
116	Drug Induced Autoimmune Hepatitis by Amoxicillin-Clavulanate. <b>2016</b> , 45, 540-1	0
115	Palbociclib-Induced Liver Failure. <b>2020</b> , 13, 81-82	2
114	[Expert panel consensus statement on prevention and standardized treatment of drug-induced liver injury in patients with blood diseases (2016)]. <b>2016</b> , 37, 441-52	0
113	Orthotopic Liver Transplantation for Etanercept-induced Acute Hepatic Failure: A Case Report. <b>2020</b> , 15, 338-341	
112	[Consensus of Chinese experts on prevention and standardized treatment of drug-induced liver injury in patients with blood diseases (2021)]. <b>2021</b> , 42, 185-192	
111	Hepatotoxicidad colestática asociada a tratamiento con enoxaparina. <b>2021</b> , 2, 579-582	
110	Dual Targeting of Cancer Cells and MMPs with Self-Assembly Hybrid Nanoparticles for Combination Therapy in Combating Cancer.. <b>2021</b> , 13,	2
109	Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management. <b>2021</b> ,	2

- 108 Methods for Identifying Culprit Drugs in Cutaneous Drug Eruptions: A Scoping Review. **2021**, 12034754211027509
- 107 Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction.. **2021**, 11, 3685-3726 3
- 106 Drugs and Toxins Affecting Liver Vessels. **2022**, 345-363
- 105 Olanzapine-induced liver injury and the correlation with body weight gain: A case report. **2020**, 34, 53
- 104 Who can? RUCAM? RECAM?. **2022**, 0
- 103 A Revised Electronic Version of RUCAM for the Diagnosis of Drug Induced Liver Injury.. **2022**, 9
- 102 Olaparib-Induced Immune-Mediated Liver Injury.. **2022**, 9, e00735
- 101 Orthotopic Liver Transplantation for Etanercept-Induced Acute Hepatic Failure; a case report. **2020**, 15, 338-341
- 100 Overview of important methods used for causality assessment of adverse drug events in pharmacovigilance. **2020**, 1, 6-12 1
- 99 Syndrome DRESS: da un caso clinico particolare alla rivisitazione della patologia. **2022**, 25, 10-16
- 98 Immunotherapy and Gene Therapy: New Challenges in the Diagnosis and Management of Drug-Induced Liver Injury.. **2021**, 12, 786174 0
- 97 Vedolizumab-induced cholestatic liver injury. **2022**, 45, 64-65
- 96 Disulfiram hepatotoxicity: Report of three cases. **2022**, 158, 145-146
- 95 Adenovirus Hepatitis in Immunocompetent Adults.. **2022**, 10, 23247096221079192 2
- 94 Quand faut-il poser une hépatite médicamenteuse chez l'enfant?. **2022**,
- 93 Age-Associated Risk of Liver-Related Adverse Drug Reactions.. **2022**, 9, 832557 0
- 92 A novel phenotype-based drug-induced liver injury causality assessment tool (DILI-CAT) allows for signal confirmation in early drug development.. **2022**, 2
- 91 Using herbs medically without knowing their composition: are we playing Russian roulette?. **2022**, 1-10

90	Rare case of norethisterone-induced hepatitis: A case report.. <b>2022</b> , 10, e05687	1
89	Incidence and risk factors of drug-induced liver injury.. <b>2022</b> ,	0
88	Artificial Intelligence in Pharmacovigilance and Covid-19.. <b>2022</b> ,	0
87	Effects of carnosic acid on arsenic-induced liver injury in mice: A comparative transcriptomics analysis.. <b>2022</b> , 71, 126953	0
86	Acute liver injury following methylprednisolone pulse therapy: 13 cases from a prospectively collected cohort.. <b>2022</b> , 34, 457-461	0
85	.. <b>2021</b> ,	0
84	Causality Evaluation of Drug-Induced Liver Injury in Newborns and Children in the Intensive Care Unit Using the Updated Roussel Uclaf Causality Assessment Method.. <b>2021</b> , 12, 790108	0
83	Recent advance of fluorescent probes for detection of drug-induced liver injury markers. <b>2021</b> ,	1
82	Observation of Voriconazole in the Treatment of Liver Failure Complicated With Invasive Pulmonary Fungal Infection Induced by Chinese Patent Medicine in Teenagers: 2 Case Reports.. <b>2022</b> , 13, 862222	0
81	An activatable fluorescent probe for monitoring the up-regulation of peroxynitrite in drug-induced hepatotoxicity model. <b>2022</b> , 110341	1
80	Data_Sheet_1.docx. <b>2020</b> ,	
79	Image_1.TIF. <b>2019</b> ,	
78	Image_2.TIF. <b>2019</b> ,	
77	Image_3.TIF. <b>2019</b> ,	
76	Image_4.TIF. <b>2019</b> ,	
75	Image_5.TIF. <b>2019</b> ,	
74	Image_6.TIF. <b>2019</b> ,	
73	Table_1.docx. <b>2019</b> ,	

- 72 DataSheet\_1.docx. **2020**,
- 71 Retreatment with Checkpoint inhibitors after a severe immune-related hepatitis: Results from a prospective multicenter study.. **2022**, 0
- 70 Severe DILI in a Patient Under Polypharmacy Including Rosuvastatin: Diagnostic Challenges and Lessons from a Case Report Assessed Using the updated RUCAM algorithm. **2022**, 01,
- 69 Liver Injury in COVID-19 Patients with Drugs as Causatives: A Systematic Review of 996 DILI Cases Published 2020/2021 Based on RUCAM as Causality Assessment Method.. **2022**, 23, 1
- 68 Abnormal liver tests are not sufficient for diagnosis of hepatic graft-versus-host disease in critically ill patients.. **2022**,
- 67 Adverse drug reactions reported to liver injury in China: Database and reporting outlines. **2022**, 0
- 66 Management of Pharmacologic Adverse Effects in Advanced Liver Disease.. **2022**, 1 0
- 65 Efficacy and safety of bicyclol for treating patients with idiosyncratic acute drug-induced liver injury: A multicenter, randomized, phase II trial.. **2022**,
- 64 Challenges and Future of Drug-Induced Liver Injury Research Laboratory Tests. **2022**, 23, 6049 1
- 63 RECAM: A New and Improved, Computerized Causality Assessment Tool for DILI Diagnosis. **2022**, Publish Ahead of Print, 0
- 62 Drug-Induced Liver Injury. **2022**, 237-263
- 61 Concurrent & de novo Thymoma-associated Paraneoplastic Type 1 Autoimmune Hepatitis and Pure Red Cell Aplasia After Thymectomy: A Case Report and Literature Review. **2022**,
- 60 Drug-induced autoimmune hepatitis: A minireview. **2022**, 28, 2654-2666 0
- 59 Editorial: chronic DILI and HILI Corticosteroid plus glycyrrhizin as standard therapy?. **2022**, 56, 166-167 0
- 58 Toward Kidney-Specific Causality Assessment Tool. **2022**, 0
- 57 Pathomechanisms of Drug Hypersensitivity Targeting the Liver and Skin. **2022**, 47-57
- 56 Molecular and Serological Testing for Brucellosis in Egypt. **2022**, 01,
- 55 A new framework for advancing in Drug-Induced Liver Injury research. The Prospective European DILI Registry. 1

- 54 A logistic regression model based on inpatient health records to predict drug-induced liver injury caused by ramipril. An angiotensin-converting enzyme inhibitor. **2022**, 17, e0272786
- 53 Is routine laboratory testing in healthy young patients taking isotretinoin necessary? A critically appraised topic. ○
- 52 AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. 1
- 51 Case report: Kinetics of human leukocyte antigen receptor HLA-DR during liver injury induced by potassium para-aminobenzoate as assessed for causality using the updated RUCAM. 13, ○
- 50 Acute fulminant hepatitis related to the use of dasatinib: First case report. **2022**, 46, 102004 ○
- 49 Metabolomic profiling for drug-induced liver injury with autoantibodies. **2022**, 111, 109084
- 48 Vanishing bile duct syndrome after drug-induced liver injury. **2022**, 46, 102015 ○
- 47 Acute Liver Injury in the setting of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome with Cocaine as suspected culprit agent: A case report. **2022**, 46, 102023 ○
- 46 Causality Assessment in Pharmacovigilance for Herbal Medicines. **2022**, 189-209 ○
- 45 Impact of pharmacist active consultation on clinical outcomes and quality of medical care in drug-induced liver injury inpatients in general hospital wards: A retrospective cohort study. 13, ○
- 44 Pharmacovigilance programme in India (PvPI): History, Current scenario, future aspects and role in COVID 19. **2022**, 205-209 ○
- 43 Atorvastatin induced liver injury: A Case Series. **2022**, 3507-3510 ○
- 42 Use and safety of appearance and performance enhancing supplements in gay, bisexual, and other men who have sex with men receiving daily tenofovir disoproxil fumarate/emtricitabine as HIV pre-exposure prophylaxis. 1-7 ○
- 41 Drug-induced liver injury associated with dacomitinib: A case report. 12, ○
- 40 Literature review of the clinical characteristics of metformin-induced hepatotoxicity. 13, ○
- 39 A novel quantitative computer-assisted drug-induced liver injury causality assessment tool (DILI-CAT). **2022**, 17, e0271304 ○
- 38 Modeling drug-induced liver injury: current status and future prospects. **2022**, 18, 555-573 ○
- 37 Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials. **2022**, 1

36	Frequency of drug-induced liver injury in children receiving anti-staphylococcal penicillins.	o
35	Transplantation of adipose-derived mesenchymal stem cells ameliorates acute hepatic injury caused by nonsteroidal anti-inflammatory drug diclofenac sodium in female rats. <b>2022</b> , 155, 113805	o
34	Green Tea ( <i>Camellia sinensis</i> ). <b>2022</b> , 451-457	o
33	Kratom-Associated Mixed Cholestatic-Hepatocellular Liver Injury in a Patient With Long COVID: A case Report. <b>2022</b> , 15, 117954762211328	o
32	Plasma metabolomic and lipidomic alterations associated with anti-tuberculosis drug-induced liver injury. 13,	o
31	Diagnosing Drug-Induced Liver Injury. <b>2023</b> , 243-253	o
30	Clinical assessment of suspected drug-induced liver injury and its management.	o
29	New insights into herb-induced liver injury.	o
28	Drug-induced liver injury: A primer for cardiologists. <b>2022</b> , 11, 79	o
27	Drug-induced liver injury in COVID-19 treatment: Incidence, mechanisms and clinical management. 13,	o
26	Assessment of the Frequency, Phenotypes, and Outcomes of Acute Liver Injury Associated with Amoxicillin/Clavulanate in 1.4 Million Patients in the Veterans Health Administration.	o
25	Clinical and Liver Biochemistry Phenotypes, and Outcome in 133 Patients with Anti-seizure Drug-Induced Liver Injury.	o
24	Treatment of Drug-Induced Liver Injury. <b>2023</b> , 11, 15	1
23	Ceftriaxone-induced cholestatic hepatitis in a child: A case report and a review of the literature. 10,	o
22	COVID-19 drug-induced liver injury: A recent update of the literature. 28, 6314-6327	o
21	Green tea extract-associated acute liver injury: Case report and review. <b>2022</b> , 20, 181-187	o
20	Severe Drug-Induced Liver Injury From Over-the-Counter Medication. <b>2023</b> ,	o
19	Experimental Approaches and Generating the Evidence. <b>2023</b> , 1-17	o

- 18 Drug-induced liver injury: An overview and update. **2023**, ○
- 17 The Impact of Patient Age and Corticosteroids in Patients With Sulfonamide Hepatotoxicity. **2023**, Publish Ahead of Print, ○
- 16 Molecular Idiosyncratic Toxicology of Drugs in the Human Liver Compared with Animals: Basic Considerations. **2023**, 24, 6663 ○
- 15 A series of homeopathic remedies-related severe drug-induced liver injury from South India. **2023**, 7, e0064-e0064 ○
- 14 Autoimmunity associates with severity of illness in elderly patients with drug-induced liver injury. 14, ○
- 13 Selective Androgen Receptor Modulators (SARMs)-Induced Liver Injury: A Case Report and Review of Literature. **2023**, ○
- 12 Drug-induced liver injury caused by conventional drugs, using cases based on the Roussel Uclaf causality assessment method. **2023**, 385-407 ○
- 11 Intrahepatic infiltration of activated CD8+ T cells and mononuclear phagocyte is associated with idiosyncratic drug-induced liver injury. 14, ○
- 10 Tandem mass tag-based quantitative proteomic profiling identifies candidate serum biomarkers of drug-induced liver injury in humans. **2023**, 14, ○
- 9 An Immunological Perspective on the Mechanism of Drug Induced Liver Injury: Focused on Drugs for Treatment of Hepatocellular Carcinoma and Liver Transplantation. **2023**, 24, 5002 ○
- 8 Toxicity patterns associated with chronic ketamine exposure. **2023**, ○
- 7 Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort. **2023**, 5, 100719 ○
- 6 Liver Transplantation for Fulminant Hepatic Failure Precipitated by Pheochromocytoma Crisis in the Setting of Using Garcinia cambogia Weight Loss Supplement: A Case Report. **2023**, ○
- 5 Drug-induced liver injury in COVID-19 patients during hospitalization. **2023**, 102, e33294 ○
- 4 Molecular and Clinical Links between Drug-Induced Cholestasis and Familial Intrahepatic Cholestasis. **2023**, 24, 5823 ○
- 3 Drug-induced liver injury: a comprehensive review. **2023**, 16, 175628482311634 ○
- 2 Hepatic Injury due to Drugs, Dietary and Herbal Supplements, Chemicals and Toxins. **2024**, 726-841 ○
- 1 Drug-induced liver injury associated with the use of newer antiseizure medications in the elderly: an analysis of data from VigiBase. ○

